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Abstract
Vascular endothelial growth factor (VEGF), through its activation of cell surface receptor tyrosine kinases including VEGFR1
and VEGFR2, is a vital regulator of stimulatory and inhibitory processes that keep angiogenesis – new capillary growth from
existing microvasculature – at a dynamic balance in normal physiology. Soluble VEGF receptor-1 (sVEGFR1) – a naturally-
occurring truncated version of VEGFR1 lacking the transmembrane and intracellular signaling domains – has been
postulated to exert inhibitory effects on angiogenic signaling via two mechanisms: direct sequestration of angiogenic
ligands such as VEGF; or dominant-negative heterodimerization with surface VEGFRs. In pre-clinical studies, sVEGFR1 gene
and protein therapy have demonstrated efficacy in inhibiting tumor angiogenesis; while in clinical studies, sVEGFR1 has
shown utility as a diagnostic or prognostic marker in a widening array of angiogenesis–dependent diseases. Here we
developed a novel computational multi-tissue model for recapitulating the dynamic systemic distributions of VEGF and
sVEGFR1. Model features included: physiologically-based multi-scale compartmentalization of the human body; inter-
compartmental macromolecular biotransport processes (vascular permeability, lymphatic drainage); and molecularly-
detailed binding interactions between the ligand isoforms VEGF121 and VEGF165, signaling receptors VEGFR1 and VEGFR2,
non-signaling co-receptor neuropilin-1 (NRP1), as well as sVEGFR1. The model was parameterized to represent a healthy
human subject, whereupon we investigated the effects of sVEGFR1 on the distribution and activation of VEGF ligands and
receptors. We assessed the healthy baseline stability of circulating VEGF and sVEGFR1 levels in plasma, as well as their
reliability in indicating tissue-level angiogenic signaling potential. Unexpectedly, simulated results showed that sVEGFR1 –
acting as a diffusible VEGF sink alone, i.e., without sVEGFR1-VEGFR heterodimerization – did not significantly lower
interstitial VEGF, nor inhibit signaling potential in tissues. Additionally, the sensitivity of plasma VEGF and sVEGFR1 to
physiological fluctuations in transport rates may partially account for the heterogeneity in clinical measurements of these
circulating angiogenic markers, potentially hindering their diagnostic reliability for diseases.
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Introduction
The VEGF System in Angiogenesis
Vascular endothelial growth factor (VEGF) – a family of
cytokines that include VEGF-A, VEGF-B and placental growth
factor, PlGF – is central to the regulation of competing stimulatory
and inhibitory biochemical reactions that keep vascular angiogen-
esis – the growth of new blood capillaries from existing
microvasculature – at a critical homeostasis in normal physiology
[1–3]. VEGF121, VEGF165, VEGF189 are considered the predom-
inant pro-angiogenic isoforms of human VEGF-A (UniProt
accession P15692); their mRNA expression levels in muscle tissues
have been found to range from 3:4:3 in humans [4] to 8:77:15
(VEGF120:VEGF164:VEGF188) in mice [5]. Their endogenous
prevalence makes VEGF121 and VEGF165 common therapeutic
agents in pro-angiogenic treatment for ischemic pathologies such
as peripheral arterial disease (PAD) and coronary artery disease
(CAD) [1,6]. Once secreted into the extracellular matrix,
VEGF121 is generally considered a freely diffusible isoform, while
VEGF165 and VEGF189 can be sequestered through its heparin-
binding domain at interstitial and cell surface proteoglycans in
significant quantities. Among the major endothelial cell surface
receptor targets for these VEGF isoforms are: the tyrosine kinases
VEGFR1 (Flt-1; UniProt accession P17948-1) and VEGFR2
(mouse Flk-1; human KDR; UniProt accession P35968); as well as
the co-receptor neuropilin-1 (NRP1; UniProt accession O14786),
which couples directly with VEGFR1, and indirectly with
VEGFR2 through non-overlapping binding sites on VEGF165 [7].
Soluble VEGF Receptor-1
Soluble VEGFR1 (sVEGFR1; UniProt accession P17948-2),
also known as soluble fms-like tyrosine kinase receptor-1 (sFlt-1), is
a naturally-occurring truncated 110-kDa version of the 180-kDa
membrane-spanning VEGFR1 [8,9], derived predominantly from
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contributions from proteolytic shedding of the extracellular
fragment of VEGFR1 as well [10–12]. While lacking the
transmembrane and intracellular signaling domains of VEGFR1,
sVEGFR1 retains the protein structure and molecular function-
ality of the first six immunoglobulin-like extracellular domains of
VEGFR1: i.e., an affinity for VEGF ligands, the NRP1 co-
receptor, and extracellular heparan sulfate proteoglycans, as well
as a capacity for homo/hetero-dimerization [13–15].
Studies have shown that the anti-angiogenic property of
sVEGFR1 plays a critical role in the normal physiology of
maintaining corneal avascularity [16] and in the pathology of the
pregnancy disorder, pre-eclampsia [17,18]. Recently, sVEGFR1
has been implicated in the impaired ischemic muscle angiogenesis
of PAD. In diabetic mouse models of PAD, muscle expression of
VEGF and sVEGFR1 both increased after surgically-induced
hindlimb ischemia [19]. In clinical trials of therapeutic angiogen-
esis for CAD and PAD, the inconsistent efficacy of VEGF protein/
gene therapy prompted a hypothesis that patients of these
atherosclerotic vascular diseases may suffer from ligand insensi-
tivity due to impaired receptor signaling or altered expression of
antagonists (e.g., sVEGFR1), rather than simply a lack of
angiogenic growth factors themselves [6].
It has been postulated that sVEGFR1 inhibits VEGF-signaling
via two molecular mechanisms – (1) direct ligand trapping of
VEGF ligands; and (2) heterodimerization with surface VEGFR
monomers to form dominant-negative receptor dimers [9,20] –
though their relative functional contributions in vivo are not known.
Nonetheless, pre-clinical studies on sVEGFR1 gene/protein
therapy have already shown success in interfering with VEGF-
dependent pathological processes including tumor angiogenesis
[21–30], ocular neovascularization [31,32], inflammation [33–35]
and edema [36].
Furthermore, researchers are increasingly finding clinical utility
for sVEGFR1, either independently or in combination with
circulating VEGF or PlGF, as diagnostic and prognostic markers
for a diversity of angiogenesis-dependent medical conditions: from
astrocytic gliomas [37], primary breast cancer [38], acute myeloid
leukemia [39], to sepsis [40], and pre-eclampsia [41,42]. In PAD,
while plasma VEGF has been correlated with disease severity [43],
there is contradicting evidence regarding whether plasma
sVEGFR1 level is significantly lowered relative to healthy controls
[43–46]. A key issue hindering the reliability of circulating
sVEGFR1 levels as surrogate markers of the angiogenic status in
angiogenesis-dependent pathologies is the striking inter-study and
intra-study heterogeneity in clinical measurements of plasma
sVEGFR1 for healthy control subjects [39,40,42–52] – a
variability of over several orders of magnitude which may be
attributable to inter-study methodological differences, as well as
natural variation at physiological baseline among individuals
within control groups [44,53].
Hence we identified the need for a computational model that
predicts the systemic distributions and molecular interactions of
VEGF and sVEGFR1 across the human body, to serve as a
platform for the mechanistic study of sVEGFR1’s purported anti-
angiogenic properties, as well as the pre-clinical study of
sVEGFR1 as a disease marker and therapeutic agent.
Computational Systems Biology Modeling
We have previously developed several computational models of
the in vivo biochemical interactions between VEGF121, VEGF165,
VEGFR1, VEGFR2, NRP1, and the interstitial matrix in skeletal
muscle, including: a spatially-averaged single-tissue model of the
human vastus lateralis muscle at rest [54]; and several 3D models
for predicting spatial molecular gradients and intra-muscular pro-
angiogenic treatment outcomes in resting and exercising rat
extensor digitorum longus muscle [55–58]. A recent extension has
been to develop a multi-tissue lumped-compartment framework to
describe the systemic distributions of VEGF across the human
body; a first application to study human breast cancer introduced
macromolecular transport between the blood, healthy solid tissue
and tumor compartments through vascular permeability [59]. In
the present study, further model extensions have been made to
include: (i) sVEGFR1, an endogenous antagonist of VEGF, into
the network of molecular interactions; as well as (ii) lymphatic
drainage, as a second mode of macromolecular transport from the
solid tissue compartments into the blood.
Lymphatic Drainage of sVEGFR1
The lymphatic vasculature is a one-way drainage system that
returns fluid and proteins from the interstitial spaces of tissues into
the blood [60]. The inclusion of lymphatic drainage in the
modeling of sVEGFR1 biodistribution was particularly relevant
for two reasons. Firstly, relative to VEGF (,46-kDa dimer [10]),
sVEGFR1 (,220-kDa dimer [8]) is expected to rely more on
lymphatic drainage to clear its interstitial accumulation, because
its larger molecular size theoretically should hinder blood capillary
reabsorption (vascular permeability), and it also has relatively
fewer routes of receptor-mediated internalization (especially if
heterodimerization with surface receptors proves insignificant).
Secondly, the lymphatic capillaries in skeletal muscle rely on the
‘‘milking effect’’ of rhythmical contractions and relaxations by
adjacent skeletal muscle for lymph propulsion [61,62]. As lymph
flow directly transfers protein mass from the interstitial space into
the blood, concentrations of VEGF and sVEGFR1 in muscle
interstitia and in plasma could be sensitive to the muscle activity-
dependent changes in lymph flow rates. Hence we hypothesized
that the physiological activity-dependent fluctuations in lymphatic
drainage rates may contribute to the clinical heterogeneity
observed in plasma measurements of VEGF and sVEGFR1.
The implications of such an association would be significant: (i)
impaired ambulation (due to the PAD symptoms of intermittent
claudication) and the associated reductions in leg muscle
contractions and lymph flow rate may partially account for the
tissue edema [62] and lowered plasma sVEGFR1 levels observed
in PAD [44,45]; conversely, (ii) the success of exercise rehabilita-
tion for PAD patients can potentially be explained by the
restoration of lymph flow rate with increased leg muscle
contractions [61,63,64].
Objectives and Achievements
In summary, the goals of this study were: (1) to develop a
computational multi-tissue model for recapitulating the systemic
distributions of VEGF and sVEGFR1; (2) to parameterize the
model for a healthy human subject; and (3) to investigate the
effects of sVEGFR1 and lymphatic drainage on the VEGF ligand-
receptor system. Firstly, we explored whether sVEGFR1 – in its
capacity as a VEGF sink alone (without heterodimerization with
surface VEGFRs) – can demonstrate anti-angiogenic potential,
e.g., lowering free VEGF availability and inhibiting signaling
complex formation. Secondly, we tested the hypothesis that
physiological fluctuations in transport rates – especially the muscle
activity-dependent lymphatic drainage rates – contribute to the
natural variability in plasma concentrations of VEGF and
sVEGFR1 as observed clinically. Taken together, the results
yielded an assessment of the general utility of plasma VEGF and
sVEGFR1 levels as surrogate markers for the angiogenic status in
diseases, specifically regarding their stability (i.e., whether their
Systemic Effects of sVEGFR1
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ical perturbations in system parameters including transport rates)
and reliability (i.e., whether their changes correlated with
interstitial changes in angiogenic signaling potential).
Materials and Methods
1. Compartmental Model Formulation
To model the systemic distributions of VEGF and sVEGFR1
associated with healthy subjects, a physiologically-based pharma-
cokinetic model was constructed that divided the human body into
three compartments: (1) the ‘‘calf’’, consisting of the gastrocnemius
and soleus muscles; (2) the ‘‘normal (rest of the body)’’, consisting of all
other solid tissues; and (3) the ‘‘blood’’, that interacts with the other
two compartments. The purpose of distinguishing a calf
compartment was two-fold: (a) to investigate the differential effects
of varying local (calf) vs. global (body) parameters in the present
study; and (b) in preparation for future modelling of and
comparative investigations against PAD patients whose calf
muscles are common symptomatic sites of tissue ischemia and
impaired angiogenesis [43,65]). Further spatial distinctions within
the tissue compartments into parenchymal space, interstitial space
and capillary space were necessary to distinguish tissue-specific
pools of VEGF and sVEGFR1 into free vs. matrix-bound vs.
receptor-bound subpopulations. As illustrated in Fig. 1A, histo-
logical data from cross-sections of healthy human muscles were
used to characterize the relevant volumes and surface areas of
these spatial subdivisions for the tissue compartments.
Within the tissue compartments, free VEGF121 and VEGF165
were secreted from parenchymal cells (myocytes) in a 1:10 ratio in
correspondence with the mRNA expression ratio of freely diffusible
isoforms (VEGF120) vs. heparin-binding isoforms (VEGF164+
VEGF188) in mice [5]. Free sVEGFR1 was secreted abluminally
from endothelial cells into the interstitial space (Fig. 1B); luminal
secretion of sVEGFR1 was neglected in congruency with model
assumptions to neglect luminal insertion of membrane-tethered
VEGFRs (for which there is little quantitive evidence and will be
separately investigated in further studies). Proteolytic shedding of
sVEGFR1 from abluminal surface VEGFR1 was neglected in our
model, as was VEGF165 proteolysis by plasmin and MMPs [66].
Tissue concentrations of VEGF and sVEGFR1 were then
distributed – through competing binding interactions summarized
in Fig. 1C – over three populations: (i) diffusing freely or as VEGF-
sVEGFR1 complexes within the available interstitial fluid; (ii)
sequestered in the endothelial basement membrane (EBM),
extracellular matrix (ECM), and parenchymal basement membrane
(PBM) regions of the interstitial space, each with distinct composi-
tions of VEGF- and sVEGFR1-binding proteoglycans; or (iii) bound
to abluminal endothelial cell surface receptors. The binding
interactions of sVEGFR1, in particular, were inferred functionalities
based on the first six Ig-like domains that it has in common with
VEGFR1 (Fig. 1D). Since the current implementation neglected
heterodimerization of sVEGFR1 with surface VEGFRs, internali-
zation of sVEGFR1 from the endothelial surface could only occur
through binding to surface NRP1s; while VEGF could be
internalizedthrough thesix signalingVEGFR complexes inaddition
to uncoupled NRP1s (Fig. 1B,C). Additionally, the soluble
volumetric species – free VEGF, free sVEGFR1 and VEGF-
sVEGFR1 complex – were subjected to inter-compartmental
transport processes: (i) lymphatic drainage from the interstitium into
plasma; (ii) bidirectional vascular permeability between interstitial
fluid and plasma; and (iii) direct clearance from plasma (Fig. 1B).
In this spatially-averaged model, gradients of soluble species
were neglected within the interstitial fluid (where diffusion time
was faster than reaction time as justified by Damkohler number
,1 [54]) and plasma. Spatial variability in matrix- or receptor-
binding was also neglected.
As in our previous compartmental models [54,67], surface
receptors were present only in pre-associated homodimeric form,
i.e., the biophysical dynamics of VEGF-induced receptor dimer-
ization and VEGFR1-VEGFR2 heterodimers were both ignored,
for the lack of in vivo validation despite in vitro [68,69] and
theoretical evidence [70].
Although in vitro studies had found sVEGFR1, in both
monomeric and dimeric forms, to be able to form complexes with
VEGF in significant amounts in HUVEC-conditioned media
[8,10], there is currently no in vivo data on their relative quantities
or the dimerization mechanism (whether some sVEGFR1 are
secreted as homodimers or whether dimerization is ligand-
dependent). Thus in parallel to our surface receptors, sVEGFR1
wasmodeled asauniformspeciesofpre-associatedhomodimersasa
first approximation. Furthermore, sVEGFR1-heterodimerization
with surface VEGFRs (i.e., the association between monomeric
sVEGFR1 and surface VEGFR monomers) was neglected in this
first study to independently investigate sVEGFR1’s VEGF-trapping
function (Fig. 1C: interactions ‘T1-3’).
2. Molecular Interactions & Transport Equations
In the mathematical formulation of our model, a system of 61
coupled nonlinear ordinary differential equations (ODEs) was used
to describe the temporal dependence of each molecular species’
tissue and blood concentrations on their binding interactions and
transport processes. Protein concentrations, when expressed in the
notations of [X]j and [X]B, as in the ODEs below, are in units of
‘‘moles/cm
3 of tissue j’’ and ‘‘moles/cm
3 of blood’’ respectively.
Elsewhere, separate notations [X]IS,j and [X]pl refer to these
concentrations in units of M, as converted to their relevant fluid
volume basis, i.e., ‘‘moles/L of available interstitial fluid in tissue j’’
and ‘‘moles/L of plasma’’ respectively. The ‘‘available’’ interstitial
fluid volume excludes all interstitial fluid spaces that are
inaccessible to molecules, including isolated pores (e.g., fluid
spaces trapped during matrix deposition) and steric exclusion
spaces near solid surfaces (e.g. bound water) [59,71]. Conversions
between the two sets of notations are as follows:
X ½  IS,j~
X ½  j
KAV,j
, KAV,j~
UIS,j
Uj
~
available interstitial fluid volume
total volume of tissuej
KAV,j~Available Volume Fraction~W:f:eIS
W~Partition Coefficient~
available fluid volume
interstitial fluid volume
f~Fluid Fraction~
interstitial fluid volume
interstitial space
eIS~Interstitial Fraction~
interstitial space
total tissue volume
and
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PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5108Figure 1. Schematic of Multi-Tissue Model of VEGF and sVEGFR1 Distributions. A. Whole-body compartmentalization of solid tissues into
‘Calf’ vs. ‘Normal’ (rest of the body) compartments for a healthy subject. Characteristic geometries – parenchymal cell (grayish red), interstitial space
(green/blue) and capillary space (endothelial cells (EC) in yellow, plasma in pink, red blood cells (RBC) in red) volume fractions; basement
membrane (BM) thicknesses; and EC surface areas – were quantified from histological cross-sections of representative human skeletal
muscles (gastrocnemius and vastus lateralis). Illustrations adapted from: ‘muscle man’ series from Andreas Vesalius, De Humani Corpis
Fabrica, 1543, courtesy of the National Library of Medicine; histological micrographs from Baum et al. J Vasc Res 2007;44:202–213. Note: BM
thicknesses and molecule sizes are not drawn to scale. B. Mass flows through 3-compartment model. VEGF and sVEGFR1 were secreted from
parenchymal and endothelial cell sources respectively. Both were internalized upon binding with abluminal endothelial surface receptors. All
soluble species were subjected to lymphatic drainage from interstitial space into the blood, bidirectional permeability through the
endothelia, and direct clearance from the blood. C. Molecular Interactions between VEGF121 (yellow), VEGF165 (blue), sVEGFR1 (orange),
interstitial matrix binding sites (glycosaminoglycans or ‘‘GAG’’; purple), and the abluminal endothelial cell surface receptors VEGFR1 (red), VEGFR2
(blue), and NRP1 (green). The sVEGFR1 interactions modeled were: trapping of free VEGF121 (T1a) and VEGF165 (T2); giving NRP1s an indirect
way of sequestering VEGF121 to the cell surface (T1b or T3); and displacing VEGF165 from interstitial matrix sites (D1b) through competitive
binding (D1a). This model neglected sVEGFR1-heterodimerization with surface VEGFRs, thus ignoring the possible effect of sVEGFR1 in
lowering the effective density of functional surface VEGFRs. Hence in this study, any effect that the presence of sVEGFR1 had on VEGF-
signaling potential (i.e, the formation of VEGF-VEGFR complexes) resulted from sVEGFR1’s influence on the effective concentration of
interstitial free VEGF. D. Protein domains of full-length vs. soluble human VEGFR1. sVEGFR1’s binding affinities for the VEGF ligand, interstitial
matrix sites (e.g., heparan sulfate proteoglycans) and NRP1 were inferred from the identical first 6 immunoglobulin-like domains of the full-
length VEGFR1.
doi:10.1371/journal.pone.0005108.g001
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X ½  B
KAV,B
, KAV,B~
Upl
UB
~
plasma volume
total blood volume
2.1 Tissue Equations
Each tissue compartment j={N for Normal; D for Calf} contained
28 molecular species whose governing equations were as follows:
i. Interstitial Matrix. The following 9 equations describe the
occupancies of VEGF- and sVEGFR1-binding sites in the
interstitial matrix. Here, [M] denotes the concentration of matrix
binding sites in the ECM, EBM, or PBM as specified in subscripts;
[V165] the interstitial concentration of free VEGF165;[ sR1] the
interstitial concentration of free sVEGFR1; kon (moles/cm
3 tissue/s)
and koff (s
21) are the kinetic rates for binding and unbinding
respectively. The current model assumed the subsequent binding of
free VEGF165 onto matrix-bound sVEGFR1 or of free sVEGFR1
onto matrix-bound VEGF165 to be negligible; no experimental data
on these spatial configurations were available. The unconfirmed
binding of VEGF-sVEGFR1 complexes directly onto unoccupied
matrix sites was also neglected.
dM EBM ½  j
.
dt~{kon,V165:M,j V165 ½  j MEBM ½  j
zkoff,V165:M,j V165:MEBM ½  j
{kon,sR1:M,j sR1 ½  j MEBM ½  j
zkoff,sR1:M,j sR1:MEBM ½  j
dM ECM ½  j
.
dt~{kon,V165:M,j V165 ½  j MECM ½  j
zkoff,V165:M,j V165:MECM ½  j
{kon,sR1:M,j sR1 ½  j MECM ½  j
zkoff,sR1:M,j sR1:MECM ½  j
dM PBM ½  j
.
dt~{kon,V165:M,j V165 ½  j MPBM ½  j
zkoff,V165:M,j V165:MPBM ½  j
{kon,sR1:M,j sR1 ½  j MPBM ½  j
zkoff,sR1:M,j sR1:MPBM ½  j
dV 165:MEBM ½  j
.
dt~kon,V165:M,j V165 ½  j MEBM ½  j
{koff,V165:M,j V165:MEBM ½  j
dV 165:MECM ½  j
.
dt~kon,V165:M,j V165 ½  j MECM ½  j
{koff,V165:M,j V165:MECM ½  j
dV 165:MPBM ½  j
.
dt~kon,V165:M,j V165 ½  j MPBM ½  j
{koff,V165:M,j V165:MPBM ½  j
ds R 1:MEBM ½  j
.
dt~kon,sR1:M,j sR1 ½  j MEBM ½  j
{koff,sR1:M,j sR1:MEBM ½  j
ds R 1:MECM ½  j
.
dt~kon,sR1:M,j sR1 ½  j MECM ½  j
{koff,sR1:M,j sR1:MECM ½  j
ds R 1:MPBM ½  j
.
dt~kon,sR1:M,j sR1 ½  j MPBM ½  j
{koff,sR1:M,j sR1:MPBM ½  j
ii. Abluminal Endothelial Cell Surface. The next 14
equations describe the ligand-binding and co-receptor-coupling
status of abluminal endothelial surface receptors. Notation for the
densities of these surface species are: [R1], [R2] and [N1] for
unoccupied VEGFR1, VEGFR2 and NRP1 respectively; [VR]
and [VN] for VEGF-bound VEGFRs and NRP1 respectively;
[RVN] and [VRN] for NRP1-coupled VEGF-ligated VEGFRs. kc
(moles/cm
3 tissue/s) denotes the coupling rate between a VEGFR
and the co-receptor NRP1; kdissoc (s
21) denotes the direct
decoupling of VEGFR1 and NRP1. kint (s
21) is the
internalization rate of free or bound receptors; while sR is the
insertion rate of free receptors back into the cell membrane. In this
study, kint was assumed to be identical for all free receptors and
complexes, though there is possibility for future investigation of
differential internalization rates for phosphorylated and
unphosphorylated receptors. There was also no feedback
regulation of receptor expression as a function of VEGF
signaling: i.e., constant total (free + occupied) receptor densities
were maintained by defining sR=kint?[R total]. Curly brackets
contain the terms referring to the direct binding interaction
between VEGF121 and NRP1, which were turned off (kon=0) in
the base case and tested during sensitivity analyses.
dR 1 ½  j
.
dt~sR1,j{kint,R1,j R1 ½  j
{kon,V:R1,j V121 ½  j R1 ½  jzkoff,V:R1,j V121:R1 ½  j
{kon,V:R1,j V165 ½  j R1 ½  jzkoff,V:R1,j V165:R1 ½  j
{kc,R1:N1,j R1 ½  j N1 ½  jzkdissoc,R1:N1,j R1:N1 ½  j
dR 2 ½  j
.
dt~sR2,j{kint,R2,j R2 ½  j
{kon,V:R2,j V121 ½  j R2 ½  jzkoff,V:R2,j V121:R2 ½  j
{kon,V:R2,j V165 ½  j R2 ½  jzkoff,V:R2,j V165:R2 ½  j
{kc,R2:VN1,j R2 ½  j V165:N1 ½  jzkoff,R2:VN1,j R2:V165:N1 ½  j
dN 1 ½  j
.
dt~sN1,j{kint,N1,j N1 ½  j
z{ kon,V121:N1,j V121 ½  j N1 ½  jzkoff,V121:N1,j V121:N1 ½  j
no
{kon,V165:N1,j V165 ½  j N1 ½  jzkoff,V165:N1,j V165:N1 ½  j
{kc,N1:VR2,j N1 ½  j V165:R2 ½  jzkoff,N1:VR2,j R2:V165:N1 ½  j
{kc,R1:N1,j R1 ½  j N1 ½  jzkdissoc,R1:N1,j R1:N1 ½  j
{kc,R1:N1,j V121:R1 ½  j N1 ½  jzkdissoc,R1:N1,j V121:R1:N1 ½  j
{kon,sR1:N1,j sR1 ½  j N1 ½  jzkoff,sR1:N1,j sR1:N1 ½  j
{kon,sR1:N1,j V121:sR1 ½  j N1 ½  jzkoff,sR1:N1,j V121:sR1:N1 ½  j
Systemic Effects of sVEGFR1
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.
dt~{kint,V121:R1,j V121:R1 ½  jzkon,V:R1,j V121 ½  j R1 ½  j
{koff,V:R1,j V121:R1 ½  j{kc,R1:N1,j V121:R1 ½  j N1 ½  j
zkdissoc,R1:N1,j V121:R1:N1 ½  j
dV 121:R2 ½  j
.
dt~{kint,V:R2,j V121:R2 ½  jzkon,V:R2,j V121 ½  j R2 ½  j
{koff,V:R2,j V121:R2 ½  j
dV 121:N1 ½  j
.
dt~
n
{kint,V121:N1,j V121:N1 ½  j
zkon,V121:N1,j V121 ½  j N1 ½  j{koff,V121:N1,j V121:N1 ½  j
o
dV 165:R1 ½  j
.
dt~{kint,V165:R1,j V165:R1 ½  jzkon,V:R1,j V165 ½  j R1 ½  j
{koff,V:R1,j V165:R1 ½  j
dV 165:R2 ½  j
.
dt~{kint,V165:R2,j V165:R2 ½  jzkon,V:R2,j V165 ½  j R2 ½  j
{koff,V:R2,j V165:R2 ½  j
{kc,N1:VR2,j N1 ½  j V165:R2 ½  j
zkoff,N1:VR2,j R2:V165:N1 ½  j
dV 165:N1 ½  j
.
dt~{kint,V165:N1,j V165:N1 ½  jzkon,V165:N1,j V165 ½  j N1 ½  j
{koff,V165:N1,j V165:N1 ½  j
{kc,R2:VN1,j R2 ½  j V165:N1 ½  j
zkoff,R2:VN1,j R2:V165:N1 ½  j
dR 1:N1 ½  j
.
dt~{kint,R1:N1,j R1:N1 ½  jzkc,R1:N1,j N1 ½  j R1 ½  j
{kdissoc,R1:N1,j R1:N1 ½  j
{kon,V:R1,j V121 ½  j R1:N1 ½  j
zkoff,V:R1,j V121:R1:N1 ½  j
ds R 1:N1 ½  j
.
dt~{kint,sR1:N1,j sR1:N1 ½  jzkon,sR1:N1,j sR1 ½  j N1 ½  j
{koff,sR1:N1,j sR1:N1 ½  j
{kon,V:sR1,j V121 ½  j sR1:N1 ½  j
zkoff,V:sR1,j V121:sR1:N1 ½  j
dV 121:R1:N1 ½  j
.
dt~{kint,V121:R1:N1,j V121:R1:N1 ½  j
zkc,R1:N1,j V121:R1 ½  j N1 ½  j
{kdissoc,R1:N1,j V121:R1:N1 ½  j
zkon,V:R1,j V121 ½  j R1:N1 ½  j
{koff,V:R1,j V121:R1:N1 ½  j
dV 121:sR1:N1 ½  j
.
dt~{kint,V121:sR1:N1,j V121:sR1:N1 ½  j
zkon,sR1:N1,j V121:sR1 ½  j N1 ½  j
{koff,sR1:N1,j V121:sR1:N1 ½  j
zkon,V:sR1,j V121 ½  j sR1:N1 ½  j
{koff,V:sR1,j V121:sR1:N1 ½  j
dR 2:V165:N1 ½  j
.
dt~{kint,V165:R2:N1,j R2:V165:N1 ½  j
zkc,N1:VR2,j N1 ½  j V165:R2 ½  j
{koff,N1:VR2,j R2:V165:N1 ½  j
zkc,R2:VN1,j R2 ½  j V165:N1 ½  j
{koff,R2:VN1,j R2:V165:N1 ½  j
iii. Interstitial Fluid. The next 5 equations govern the
soluble species of the interstitial fluid, including the complexes
formed between the VEGF isoforms and sVEGFR1, the
concentrations of which are denoted [V?sR1].
dV 121 ½  j
.
dt~qV121,j{
kL,j
Uj
V121 ½  j
KAV,j
z
cj:SjB
Uj
: k
B?j
p,V
V121 ½  B
KAV,B
{k
j?B
p,V
V121 ½  j
KAV,j
  
z{ kon,V121:N1,j V121 ½  j N1 ½  jzkoff,V121:N1,j V121:N1 ½  j
no
{kon,V:R2,j V121 ½  j R2 ½  jzkoff,V:R2,j V121:R2 ½  j
{kon,V:R1,j V121 ½  j R1 ½  jzkoff,V:R1,j V121:R1 ½  j
{kon,V:R1,j V121 ½  j R1:N1 ½  jzkoff,V:R1,j V121:R1:N1 ½  j
{kon,V:sR1,j V121 ½  j sR1 ½  jzkoff,V:sR1,j V121:sR1 ½  j
{kon,V:sR1,j V121 ½  j sR1:N1 ½  jzkoff,V:sR1,j V121:sR1:N1 ½  j
dV 165 ½  j
.
dt~qV165,j{
kL,j
Uj
V165 ½  j
KAV,j
z
cj:SjB
Uj
: k
B?j
p,V
V165 ½  B
KAV,B
{k
j?B
p,V
V165 ½  j
KAV,j
  
{kon,V165:M,j V165 ½  j MEBM ½  jzkoff,V165:M,j V165:MEBM ½  j
{kon,V165:M,j V165 ½  j MECM ½  jzkoff,V165:M,j V165:MECM ½  j
{kon,V165:M,j V165 ½  j MPBM ½  jzkoff,V165:M,j V165:MPBM ½  j
{kon,V165:N1,j V165 ½  j N1 ½  jzkoff,V165:N1,j V165:N1 ½  j
{kon,V:R2,j V165 ½  j R2 ½  jzkoff,V:R2,j V165:R2 ½  j
{kon,V:R1,j V165 ½  j R1 ½  jzkoff,V:R1,j V165:R1 ½  j
{kon,V:sR1,j V165 ½  j sR1 ½  jzkoff,V:sR1,j V165:sR1 ½  j
Systemic Effects of sVEGFR1
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.
dt~{
kL,j
Uj
V121:sR1 ½  j
KAV,j
z
cj:SjB
Uj
: k
B?j
p,V:sR1
V121:sR1 ½  B
KAV,B
{k
j?B
p,V:sR1
V121:sR1 ½  j
KAV,j
  
zkon,V:sR1,j V121 ½  j sR1 ½  j{koff,V:sR1,j V121:sR1 ½  j
{kon,sR1:N1,j V121:sR1 ½  j N1 ½  j
zkoff,sR1:N1,j V121:sR1:N1 ½  j
dV 165:sR1 ½  j
.
dt~{
kL,j
Uj
V165:sR1 ½  j
KAV,j
z
cj:SjB
Uj
: k
B?j
p,V:sR1
V165:sR1 ½  B
KAV,B
{k
j?B
p,V:sR1
V165:sR1 ½  j
KAV,j
  
zkon,V:sR1,j V165 ½  j sR1 ½  j{koff,V:sR1,j V165:sR1 ½  j
ds R 1 ½  j
.
dt~qsR1,j{
kL,j
Uj
sR1 ½  j
KAV,j
z
cj:SjB
Uj
: k
B?j
p,sR1
sR1 ½  B
KAV,B
{k
j?B
p,sR1
sR1 ½  j
KAV,j
  
{kon,sR1:M,j sR1 ½  j MEBM ½  jzkoff,sR1:M,j sR1:MEBM ½  j
{kon,sR1:M,j sR1 ½  j MECM ½  jzkoff,sR1:M,j sR1:MECM ½  j
{kon,sR1:M,j sR1 ½  j MPBM ½  jzkoff,sR1:M,j sR1:MPBM ½  j
{kon,sR1:N1,j sR1 ½  j N1 ½  jzkoff,sR1:N1,j sR1:N1 ½  j
{kon,V:sR1,j V121 ½  j sR1 ½  jzkoff,V:sR1,j V121:sR1 ½  j
{kon,V:sR1,j V165 ½  j sR1 ½  jzkoff,V:sR1,j V165:sR1 ½  j
Free VEGF isoforms were secreted at constant rates of qV
(moles/cm
3 tissue/s) from myocytes; while free sVEGFR1 was
secreted abluminally by endothelial cells at a constant rate of qsR1
(moles/cm
3 tissue/s). The current implementation assumed no
time-dependent feedback regulation on secretion rates as a
function of VEGFR phosphorylation or internalization. In this
study, the cell sources noted above were relevant only for unit
conversion of the secretion rates to a ‘‘per cell’’ basis; i.e., the qV
and qsR1 terms would have included endothelial or non-myocyte
sources of VEGF and parenchymal sources of sVEGFR1 if these
were significant in vivo.
All interstitial soluble species were subjected to lymphatic
drainage into the blood at a rate of kL (cm
3/s), as well as
bidirectional (BRj or jRB) vascular permeability flow at rates of kP
(cm/s). SjB (cm
2), which denotes the total abluminal endothelial
surface area exposed to the interstitial space of tissue j, and c,
which is the endothelial surface area recruitment factor (see
Methods section 3.3i), along with Uj and KAV, were geometric
conversion factors that restrict the volumes of interstitial fluid and
plasma accessible to macromolecular exchange.
2.2. Blood Equations
The last 5 equations described the blood populations of the
soluble species. There were no source terms in the blood for
VEGF or sVEGFR1 (qV,B=q sR1,B=0), although luminal secretion
from the endothelium or in situ release from formed elements (e.g.,
platelets, monocytes [17]) could be explored in future implemen-
tations. In addition to the lymphatic and vascular permeability
flows, the soluble species in plasma were subjected to a third
transport process – direct clearance at a rate of kCL (s
21).
dV 121 ½  B
 
dt~{kCL,V121 V121 ½  Bz
kL,N
UB
V121 ½  N
KAV,N
z
kL,D
UB
V121 ½  D
KAV,D
z
cN:SNB
UB
: kN?B
p,V
V121 ½  N
KAV,N
{kB?N
p,V
V121 ½  B
KAV,B
  
z
cD:SDB
UB
: kD?B
p,V
V121 ½  D
KAV,D
{kB?D
p,V
V121 ½  B
KAV,B
  
{kon,V121:sR1 V121 ½  B sR1 ½  Bzkoff,V121:sR1 V121:sR1 ½  B
dV 165 ½  B
 
dt~{kCL,V165 V165 ½  Bz
kL,N
UB
V165 ½  N
KAV,N
z
kL,D
UB
V165 ½  D
KAV,D
z
cN:SNB
UB
: kN?B
p,V
V165 ½  N
KAV,N
{kB?N
p,V
V165 ½  B
KAV,B
  
z
cD:SDB
UB
: kD?B
p,V
V165 ½  D
KAV,D
{kB?D
p,V
V165 ½  B
KAV,B
  
{kon,V165:sR1 V165 ½  B sR1 ½  Bzkoff,V165:sR1 V165:sR1 ½  B
dV 121:sR1 ½  B
 
dt~{kCL,V121:sR1 V121:sR1 ½  Bz
kL,N
UB
V121:sR1 ½  N
KAV,N
z
kL,D
UB
V121:sR1 ½  D
KAV,D
z
cN:SNB
UB
: kN?B
p,V:sR1
V121:sR1 ½  N
KAV,N
 
{kB?N
p,V:sR1
V121:sR1 ½  B
KAV,B
 
z
cD:SDB
UB
kD?B
p,V:sR1
V121:sR1 ½  D
KAV,D
 
{kB?D
p,V:sR1
V121:sR1 ½  B
KAV,B
 
zkon,V121:sR1 V121 ½  B sR1 ½  B{koff,V121:sR1 V121:sR1 ½  B
dV 165:sR1 ½  B
 
dt~{kCL,V165:sR1 V165:sR1 ½  Bz
kL,N
UB
V165:sR1 ½  N
KAV,N
z
kL,D
UB
V165:sR1 ½  D
KAV,D
z
cN:SNB
UB
: kN?B
p,V:sR1
V165:sR1 ½  N
KAV,N
 
{kB?N
p,V:sR1
V165:sR1 ½  B
KAV,B
 
z
cD:SDB
UB
: kD?B
p,V:sR1
V165:sR1 ½  D
KAV,D
 
{kB?D
p,V:sR1
V165:sR1 ½  B
KAV,B
 
zkon,V165:sR1 V165 ½  B sR1 ½  B
{koff,V165:sR1 V165:sR1 ½  B
Systemic Effects of sVEGFR1
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dt~{kCL,sR1 sR1 ½  Bz
kL,N
UB
sR1 ½  N
KAV,N
z
kL,D
UB
sR1 ½  D
KAV,D
z
cN:SNB
UB
: kN?B
p,sR1
sR1 ½  N
KAV,N
{kB?N
p,sR1
sR1 ½  B
KAV,B
  
z
cD:SDB
UB
: kD?B
p,sR1
sR1 ½  D
KAV,D
{kB?D
p,sR1
sR1 ½  B
KAV,B
  
{kon,V121:sR1 V121 ½  B sR1 ½  Bzkoff,V121:sR1 V121:sR1 ½  B
{kon,V165:sR1 V165 ½  B sR1 ½  Bzkoff,V165:sR1 V165:sR1 ½  B
3. Model Parameterization for a Healthy Human
This section describes the parameterization of compartmental
geometry, binding kinetic rates, biotransport rates, and protein
expression levels necessary to solve the model system of ODEs.
3.1. Geometry
i. Healthy Calf Muscle Compartment. The healthy calf
compartment was modeled with a control volume of 868 cm
3
(unilateral gastrocnemius and soleus muscles) [72], and with the
following histological parameters taken from gastrocnemius data
of a typical sedentary healthy human, summarized in Table 1.
From the measured fiber cross-sectional area (FCSA) of
4173 mm
2 [73], the single muscle fiber was calculated to have a
diameter of 73 mm and perimeter of 261 mm (non-cylindrical
correction factor of 1.14) [54]. The myonuclear domain (MD)
defines the cytoplasmic volume per nucleus within a multinucle-
ated myocyte [74]. Assuming the gastrocnemius to have the same
linear myonuclei density of 150 nuclei/mm as that measured from
the soleus [75], the MD surface area was then calculated to be
1740 mm
2/MD. Muscle fiber density (FD) was determined to be
199 fibers/mm
2 tissue based on a reported capillary density (CD)
of 231 capillaries/mm
2 tissue and a capillary-to-fiber ratio (CF) of
1.16 [73]. This FD yielded a total muscle fiber surface area per
unit volume of tissue (FSAV) of 520 cm
2/cm
3 tissue and a total
muscle fiber volume fraction of 0.831 cm
3/cm
3 tissue.
Capillaries of the lower leg were shown to have mean lumen,
endothelium and total cross-sectional areas of 12.4, 11.6 and
24.0 mm
2 respectively [76]. The corresponding luminal and
abluminal capillary diameters were calculated to be 3.97 and
5.53 mm respectively, with an endothelium thickness of about
0.78 mm. A capillary perimeter correction factor of 1.1 [54] was
assumed to give approximate luminal and abluminal perimeters of
13.7 and 19.1 mm respectively. Together with the mentioned CD,
these values yielded a total capillary volume fraction of
0.006 cm
3/cm
3 tissue, 0.003 cm
3/cm
3 tissue of which was
vascular space. The abluminal endothelial cell surface area
(ECSA) was taken as 1000 mm
2 per endothelial cell, averaged
from hamster arteriolar [77] and dog aortic endothelial cells [78];
while the total abluminal endothelial surface area per tissue
volume (ESAV) available for ligand-receptor binding came to
44 cm
2/cm
3 tissue.
As a result, the interstitial space (IS) left between muscle fibers
and capillaries had a volume fraction of 0.163 cm
3/cm
3 tissue.
The healthy calf IS volume comprised: 0.69% endothelial
basement membrane (EBM) based on an average thickness of
254 nm [79–82]; 8.07% parenchymal basement membrane (PBM)
assuming the same thickness as the EBM; and 91.24%
extracellular matrix (ECM). Assuming collagen to be the major
component in the IS by volume, the solid fraction of the ECM,
EBM, PBM were taken as 13.4%, 45% and 45% respectively
(dividing 14.175% collagen content in interstitial space [83]
between BM and ECM volumes such that collagen density of BMs
was triple that of ECM). The resulting fluid fraction of the
interstitium – 0.137 cm
3/cm
3 tissue, consistent with measured
range of 8 to 11% [84] – was in turn only fractionally available to
permeable molecules depending on their partition coefficients (W).
Species-specific W (Table 2) were extrapolated from theoretical
calibration curves for dextran permeating through networks [85],
using the appropriate network pore size (66 nm for ECM [83];
7 nm for BMs [85]) and the corresponding hydraulic Stokes-
Einstein radii between linear polydisperse dextran and globular
VEGF-related proteins (conversion formulae from [86]). The final
available fluid volumes are summarized in Table 1.
ii. Normal (Rest of the body) Compartment. The entire
body of a 70 kg man minus the blood would weigh about 65 kg.
As a first approximation, we modeled the entire 65 kg as
homogenous skeletal muscle with a density of 1.06 g/cm
3 [87],
giving a volume of 61,321 cm
3. Subtracting from it the volume of
the healthy calf muscle, the ‘‘normal’’ compartment representing
the ‘‘rest of the body’’ was then determined to be 60,453 cm
3. The
following geometry parameters are slightly different from those we
used previously [54], as these are taken directly from human vastus
lateralis histological data, without the previous fitting requirements
to match water spaces (1.4% vascular space and 7% interstitial
fluid), nor previous adjustments based on theoretical oxygen
consumptions. This was done for consistency with how calf
compartment parameters were derived.
Muscle fiber density (FD) was determined to be 242 fibers/mm
2
tissue based on a reported capillary density (CD) of 329
capillaries/mm
2 tissue and a capillary-to-fiber ratio (CF) of 1.36
[88]. Muscle fiber cross-sectional area (FCSA) was experimentally
measured at 41506246 mm
2 [88]. Multiplying this measured
average FCSA of 4150 mm
2 and the calculated FD of 242 fibers/
mm
2 would have produced a theoretical impossibility –
1.0043 mm
2/mm
2 – reflecting overestimations in FCSA and/or
FD. Thus the vastus lateralis FCSA was taken instead at one
standard error below mean, i.e., 3904 mm
2. From this conservative
measurement of FCSA, the single muscle fiber was calculated to
have a diameter of 71 mm and perimeter of 253 mm using a
correction factor of 1.14 [54]. Keeping the assumed linear
myonuclei density of 120 nuclei/mm [54], the surface area of
the myonuclear domain (MD) was then recalculated to be
2104 mm
2/MD. The new FD also yielded a total FSAV of
611 cm
2/cm
3 tissue and a total muscle fiber volume fraction of
0.944 cm
3/cm
3 tissue.
The luminal and abluminal diameters of individual capillaries
were taken from measurements in the vastus lateralis as 4.86 and
6.39 mm respectively [89]. From these, the endothelium thickness
was calculated to be 0.77 mm, while the lumen and endothelium
CSA were calculated to be 18.6 and 13.5 mm
2 respectively, which
agree with histological measurements from the mid-thigh
(10.867.4 and 11.466.7 mm
2) [76]. Assuming the same capillary
perimeter correction factor of 1.1 [54], the luminal and abluminal
perimeters were then 16.8 and 22.1 mm respectively. Together
with the mentioned CD, these yielded a total capillary volume
fraction of 0.011 cm
3/cm
3 tissue, 0.006 cm
3/cm
3 tissue of which
was vascular space. Though the abluminal ECSA was still
1000 mm
2/EC [54], a higher CD compared to the calf
contributed to a higher abluminal endothelial surface area per
tissue volume (ESAV) of 73 cm
2/cm
3 tissue in the normal
compartment.
Accordingly, the IS remaining between muscle fibers and
capillaries had a volume fraction of 0.045 cm
3/cm
3 tissue. The
Systemic Effects of sVEGFR1
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Tissue Compartment Units Normal (Rest of Body) Healthy Calf
Reference Muscle Vastus lateralis Gastrocnemius
Value Ref Value Ref
Compartment Volume cm
3 60453 *[87,164] 868 {[72]
Individual Muscle Fibre
Diameter mm7 1 * 7 3 *
Perimeter correction factor - 1.14 [54] 1.14 [54]
Perimeter mm 253 * 261 *
FCSA mm
2 3904 [88] 4173 [73]
Myonuclei density mm
21 120 [54] 150 [75]
MDSA mm
2/MD 2104 * 1740 *
Muscle Fibre Space
Muscle Fibre Density fibers/mm
2 tissue 242 * 199 *
FSAV cm
2/cm
3 tissue 611 * 520 *
Muscle Fibre Space Volume Fraction cm
3/cm
3 tissue 94.4% * 83.1% *
Individual Capillary
Luminal Diameter mm 4.86 [89] 3.97 *
Endothelium Thickness mm 0.77 * 0.78 *
Abluminal Diameter mm 6.39 [89] 5.53 *
Perimeter correction factor - 1.1 [54] 1.1 [54]
Abluminal Perimeter mm 22.1 * 19.1 *
CCSA mm
2 32.1 * 24.0 *
i. Lumen CSA mm
2 18.6 * 12.4 [76]
ii. Endothelium CSA mm
2 13.5 * 11.6 [76]
ECSA (abluminal) mm
2/EC 1000 [54] 1000 [54]
Capillary Space
Capillary:Fiber Ratio - 1.36 [88] 1.16 [73]
Capillary Density capillaries/mm
2 tissue 329 [88] 231 [73]
ESAV (abluminal) cm
2/cm
3 tissue 73 * 44 *
Capillary Space Volume Fraction cm
3/cm
3 tissue 1.1% * 0.6% *
i. Endothelium Space cm
3/cm
3 tissue 0.4% * 0.3% *
ii. Vascular Space cm
3/cm
3 tissue 0.6% * 0.3% *
Interstitial Space
IS Volume Fraction cm
3/cm
3 tissue 4.5% * 16.3% *
IF Volume Fraction cm
3/cm
3 tissue 3.7% * 13.7% *
Available IF Volume Fraction cm
3/cm
3 tissue 3% 11%
i. Extracellular Matrix (ECM)
ECM Volume cm
3/cm
3 tissue 3.9% * 14.9% *
cm
3/cm
3 IS 86.72% * 91.24% *
Solid Fraction {{ cm
3/cm
3 ECM 13.40% [83] 13.40% [83]
Fluid Volume in ECM cm
3/cm
3 tissue 3.38% * 12.92% *
cm
3/cm
3 IF 91.13% * 94.25% *
Available Fluid Volume in ECM cm
3/cm
3 tissue 2.87% * 10.98% *
ii. Endothelial Basement Membrane (EBM)
Thickness nm 87.5 [90,91] 254 [79–82]
EBM Volume cm
3/cm
3 tissue 0.06% * 0.11% *
cm
3/cm
3 IS 1.41% * 0.69% *
Solid Fraction {{ cm
3/cm
3 EBM 45% [83] 45% [83]
Fluid Volume in EBM cm
3/cm
3 tissue 0.03% * 0.06% *
cm
3/cm
3 IF 0.94% * 0.45% *
Systemic Effects of sVEGFR1
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average thickness of 87.5 nm [90,91] (instead of the 43 nm
previously taken [54] from extreme athletes to avoid extra
exercise-trained effects [92]); 11.87% PBM assuming the same
thickness as the EBM; and 86.72% ECM. As summarized in the
Table 1, the available fluid fractions of each IS volume were
calculated using the same solid fractions and W’s as in healthy
gastrocnemius.
iii. Blood Compartment. Finally, the blood compartment
was modeled with a volume of 5L, 60% of which was plasma [93].
Ultrastructures that were not explicitly modeled include the
glycocalyx/cell-free layer or interendothelial clefts, the effects of
which were incorporated within the transport parameters described
below. Formed elements in the blood (e.g., platelets and leukocytes)
were also ignored but could be considered as binding sites and/or
sources for the soluble species in future model extensions.
3.2. Binding and Coupling Kinetics
The control values for all binding and coupling kinetic rates
(Table 3), except for the new interactions involving sVEGFR1,
were kept identical to those from our previous single-compartment
skeletal muscle model [54]. However, sensitivity analyses were
performed to explore the following wide ranges cited in literature.
VEGF affinity of VEGFR1 and VEGFR2 varied from Kd=1–
130 pM and 72–760 pM depending on culture cell type (e.g.,
HUVECs vs. tPAEs vs. HUCMECs) [94–103]. VEGF165 affinity
of NRP1s additionally varied with assay type: Kd=200–320 pM
by cell-based Scatchard [100,104] vs. 25–120 nM by cell-free
BIAcore surface plasmon resonance analysis [14,105]. In fact,
against general consensus that VEGF121 does not bind NRP1, Pan
et al. recently observed such binding at Kd=220 nM (BIAcore),
albeit at a lower affinity than the 120 nM reported for VEGF165
and NRP1 in the same study [105]. This finding coincided with
recent observations that in addition to exon 7 of VEGF (which
VEGF165 possesses while VEGF121 does not) that was traditionally
associated with NRP-binding, exon 8 (which all VEGF isoforms
have some form of) might also confer NRP-affinity [106]. We thus
tested both scenarios: adding a new interaction between VEGF121
and NRP1 at a dissociation constant 1.83 times higher than our
control Kd for VEGF165 and NRP1 (to match the Kd ratio
Tissue Compartment Units Normal (Rest of Body) Healthy Calf
Reference Muscle Vastus lateralis Gastrocnemius
Value Ref Value Ref
Available Fluid Volume in EBM cm
3/cm
3 tissue 0.01% { 0.02% {
iii. Parenchymal Basement Membrane (PBM)
Thickness nm 87.5 [80] 254 [80]
PBM Volume cm
3/cm
3 tissue 0.53% * 1.32% *
cm
3/cm
3 IS 11.87% * 8.07% *
Solid Fraction {{ cm
3/cm
3 SBM 45% [83] 45% [83]
Fluid Volume in PBM cm
3/cm
3 tissue 0.29% * 0.73% *
cm
3/cm
3 IF 7.92% * 5.30% *
Available Fluid Volume in PBM cm
3/cm
3 tissue 0.10% { 0.24% {
FCSA=fiber cross-sectional area.
MDSA=myonuclear domain surface area.
FSAV=total muscle fibre surface area per tissue volume.
CCSA=capillary cross-sectional area (EC+lumen).
ECSA=endothelial cell surface area.
ESAV=total endothelium surface area per tissue volume.
IS=interstitial space.
IF=interstitial fluid.
*calculated.
{=combined volume of lateral gastrocnemius, medial gastrocnemius, and soleus muscles (unilateral calf).
{{=approximated by collagen content.
{calculated for average partition coefficients of 0.85 in ECM and 0.325 in BM (see Table 1b).
doi:10.1371/journal.pone.0005108.t001
Table 1. Cont.
Table 2. Hydrodynamic Properties of Soluble Species.
Molecular Weight Ref Hydrodynamic (Stokes-Einstein) Radius, aE Ref Partition Coefficient, W Ref
ECM
a BM
b
VEGF 46 kDa [103] 30 A ˚ [86] 0.9 0.35 [85]
sVEGFR1 220 kDa [20] 56 A ˚ [86] 0.8 0.3 [85]
sVEGFR1-VEGF 230 kDa [8] 57 A ˚ [86] 0.8 0.3 [85]
Assumed pore sizes of
a 66 nm ECM[83].
b7 nm in BM[85].
doi:10.1371/journal.pone.0005108.t002
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Compartment In Vitro Measurements Simulation Control Values (In Vivo Conversions)
Culture Medium Blood Normal Healthy Calf Unit
Value Unit Value Value Value
VEGF binding to VEGFR1
kon 3?10
7 M
21 s
21 N/A 10
12 2.73?10
11 (mol/cm
3 tissue)
21s
21
koff 10
23 s
21
Kd 3.33?10
211 M N/A 10
215 3.67?10
215 mol/cm
3 tissue
VEGF binding to VEGFR2
kon 10
7 M
21 s
21 N/A 3.33?10
11 9.09?10
10 (mol/cm
3 tissue)
21s
21
koff 10
23 s
21
Kd 10
210 M N/A 3?10
215 1.1?10
214 mol/cm
3 tissue
VEGF121 binding to NRP1
kon 0M
21 s
21
koff 0s
21
Kd N/A M
VEGF165 binding to NRP1
kon 3.125?10
6 M
21 s
21 N/A 1.04?10
11 2.84?10
10 (mol/cm
3 tissue)
21s
21
koff 10
23 s
21
Kd 3.2?10
210 M N/A 9.6?10
215 3.52?10
214 mol/cm
3 tissue
VEGF165 binding to GAG
kon 4.2?10
5 M
21 s
21 N/A 1.4?10
10 3.82?10
9 (mol/cm
3 tissue)
21s
21
koff 10
22 s
21
Kd 2.38?10
28 M N/A 7.14?10
213 2.62?10
212 mol/cm
3 tissue
VEGFR1 coupling to NRP1
kc 10
14 (mol/cm
2)
21s
21 N/A 1.37?10
12 2.27?10
12 (mol/cm
3 tissue)
21s
21
kdissoc 10
22 s
21
VEGF?VEGFR2 coupling to NRP1
kc 3.1?10
13 (mol/cm
2)
21s
21 N/A 4.25?10
11 7.05?10
11 (mol/cm
3 tissue)
21s
21
koff 10
23 s
21
VEGF?NRP1 coupling to VEGFR2
kc 10
14 (mol/cm
2)
21s
21 N/A 1.37?10
12 2.27?10
12 (mol/cm
3 tissue)
21s
21
koff 10
23 s
21
VEGF binding to sVEGFR1 *
kon 3?10
7 M
21 s
21 5?10
10 10
12 2.73?10
11 (mol/cm
3 tissue)
21s
21
koff 10
23 s
21
Kd 3.33?10
211 M2 ?10
214 10
215 3.67?10
215 mol/cm
3 tissue
sVEGFR1 coupling to GAG {
kon 4.2?10
5 M
21 s
21 7?10
8 1.4?10
10 3.82?10
9 (mol/cm
3 tissue)
21s
21
koff 10
22 s
21
Kd 2.38?10
28 M 1.43?10
211 7.14?10
213 2.62?10
212 mol/cm
3 tissue
sVEGFR1 binding to NRP1 {
kon 5.56?10
6 M
21 s
21 9.26?10
9 1.85?10
11 5.05?10
10 (mol/cm
3 tissue)
21s
21
koff 10
22 s
21
Receptor Internalization
kint,R (free receptors) 2.8?10
24 s
21
kint,C (bound receptors) 2.8?10
24 s
21
For in vitro values: * assumed same as VEGF binding to VEGFR1 [95].
{assumed same as VEGF165 binding to GAG.
{assumed same koff as VEGFR1 coupling to NRP1, with kon calculated to match Kd from literature [14] ; the rest were taken from [54].
Conversions for in vivo values were based on geometry parameters from Table 1:
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isoforms to the exact values as Pan et al. reported. Lastly, we
explored lower VEGF-binding affinities for matrix sites, consid-
ering that our control value of VEGF165’s Kd for matrix sites was
estimated from that of FGF-2 [107], in light of indication that
VEGF165’s Kd for modified heparin could be ,6–7 times higher
than that of FGF-2 [108,109].
Regarding the new sVEGFR1 interactions with VEGF, matrix
sites and NRP1, the following assumptions were made for their
kinetic rates. In vitro experiments have characterized the VEGF-
affinity of baculovirus-expressed and HUVEC-derived human
sFlt-1 at Kd,20 and 10 pM respectively [10,20]. Given the in vitro
evidence that the soluble and full-length VEGFR1’s have similar
affinities to VEGF [95], we assumed in our model a Kd of 33 pM
for VEGF-sVEGFR1 binding, same as that previously used [54]
for VEGF-VEGFR1 binding. To the best of our knowledge,
sVEGFR1-binding affinities of various HSPGs have not been
characterized. Despite the possible heparin-binding domain
differences between VEGF and sVEGFR1, we took the effective
Kd=23.8 nM previously used [54] for VEGF binding to matrix-
sites (ensemble of various HSPGs) as the control value of our Kd for
sVEGFR1 binding to matrix-sites. BIAcore binding analysis of Flt-
1 extracellular domains (ECDs) to immobilized NRP-1 showed a
Kd of 1.8 nM [14]. Approximating sVEGFR1 as Flt-1 ECDs, we
modeled sVEGFR1’s affinity to NRP-1 with a Kd of 1.8 nM,
subsequently calculating the kon based on the same koff as full-length
VEGFR1’s dissociation from NRP1 [54].
3.3. Transport
i. Macromolecular Vascular Permeability. Here, the
vascular permeability rates (kP) characterized the
microvasculatures’ baseline (supine posture) capacity in allowing
macromolecular transport across the endothelium, as in our
previous study [59]. A new parameter representing endothelial
surface area recruitment (c) was introduced to account for changes
in the degree of perfusion within capillary beds as occurs during
physiological redistribution of blood – e.g., a c,1 would represent
effectively reduced transendothelial transport due to a larger
fraction of unperfused or non-distended capillaries.
In determining the basal vascular permeability rates for the
soluble species, their molecular weights (MW) were first converted
into their Stokes-Einstein radii (aE) based on the empirical relation
for globular proteins, aE=0.483(MW)
0.386 [86] (Table 2). The
corresponding permeability-surface area product (PS) were then
determined from a set of theoretical curves for PS vs. aE [110].
Finally, assuming a capillary surface area (S) of 70 cm
2/g muscle
tissue [111], the molecular species-specific basal permeabilities
(kp=PS/S) were obtained (Table 4).
The posture and activity-dependent surface area recruitment
factors (Table 5) were approximated as follows. The effective
vascular permeabilities of the normal ‘‘rest of the body’’
compartment were maintained at basal levels (c=1) in both
supine (lying down) and dependent (sitting/standing) positions,
a s s u m i n gt h e r et ob el i t t l ec h a n g ea f t e ra v e r a g i n gt h ep r e s s u r e /
perfusion changes to tissue masses above and below the heart
level. For the ‘‘healthy calf’’ compartment, however, the
venoarterial reflex – which normally decreases foot perfusion
in response to moving from a supine to dependent position in
compensation to the gravitational hydrostatic hypertension –
was taken into consideration. Specifically, foot skin blood
perfusion in normal subjects has been found to decrease from
7.862.2 mL/min/100 g in the supine position to 2.860.6 mL/
min/100 g in the dependent position [112]. We thus assumed
the ‘‘healthy calf’’ compartment to take on the basal perme-
abilities when at rest (c=1 for supine) and at 3/8 of the basal
levels when standing (c=0.375 for dependent). Exercise, on the
other hand, has been shown to increase capillary surface area
available for perfusion up to 26and 36resting levels in rats and
Table 4. Transport Parameters: Basal Vascular Permeability and Plasma Clearance Rates.
Basal Permeability Rates* (bidirectional) Clearance Rate from Blood
kP [cm/s] Ref kC [s
21] Ref
VEGF 4.29?10
28 [110,111] 1.08?10
23 [120]
sVEGFR1 1.86?10
28 [110,111] 5?10
26 Estimated from VEGF-traps [121,122,165]
sVEGFR1-VEGF 1.86?10
28 [110,111] 5?10
26 Assumed same as sVEGFR1 based on hydrodynamic size
*Calibrated based on hydrodynamic sizes from Table 1b.
doi:10.1371/journal.pone.0005108.t004
kon in
moles
cm3 tissue
{1
:sec{1
 !  !
~ kon in M{1:sec{1     
available IF volume fraction ðÞ |1000
i:e: 1:7, 33, 9:1|103 moles
 
cm3 tissue
   {1:sec{1
   .
M{1:sec{1   
for blood, normal and healthy calf respectively:
kon in
moles
cm3 tissue
{1
:sec{1
 !  !
~ kon in
moles
cm2 SA
{1
:sec{1
 !  !,
ESAV
i:e: 1:4, 2:3|10{2 moles
 
cm3 tissue
   {1:sec{1
   .
moles
 
cm2 SA
   {1::sec{1
  
for normal and healthy calf respectively:
doi:10.1371/journal.pone.0005108.t003
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exercising calf.
ii. Lymphatic Drainage. In mice quadriceps femoris skeletal
muscle, capillary-sized lymphatic vessels were found next to blood
capillaries between muscle fibers, but at a much lower density
[115]. Hence the small volume of the lymphatic capillary space
was not explicitly partitioned within our tissue geometries (Fig. 1A).
There is no macromolecular size-dependence in the filling of the
initial lymphatics (unlike macromolecular permeability through
blood capillaries) [62], thus protein concentrations drained
through the lymphatics were modeled as continuous with those
in the available interstitial fluid. Moreover, fluid transfer through
the lymphatics was assumed to have negligible effects on volume
and protein concentration changes in interstitial fluid and plasma.
This was consistent with our representation of vascular
permeability where only macromolecular but not hydraulic
transport was represented in the model. The following
parameterization is summarized in Table 6.
To approximate the total mass of body tissue subjected to
lymphatic drainage, the masses of organs with no lymphatic
capillaries (entire central nervous system, lens, cornea, bone, bone
marrow, epidermis [60,116]; ,14 kg [117]) and the mass of blood
(,5 kg) were first subtracted from 70-kg total body mass. The
resulting 51 kg of body tissue drained by lymphatics was then
divided between the ,0.92 kg ‘‘calf’’ [72,87] and the ,50.08 kg
‘‘normal’’ compartments. The night-time (asleep; supine position)
lymph flow per gram of human skeletal muscle was measured to be
,2 mL/h/g skeletal muscle or 5.6610
27 cm
3/s/g tissue [62].
Thus the night-time lymph flow for the ‘‘calf’’ compartment was
determined to be 0.0005 cm
3/s. Approximating all other lym-
phatically-drained organs to have the skeletal muscle lymph flow
rate yielded a lymph flow of 0.028 cm
3/s for the ‘‘normal’’
compartment. Awakeness alone (awake; supine posture) was found
to increase the average basal lymph flow rates to about 5-fold of
night values [118]; these day-time basal values were taken as the
control rates for our simulations. Additionally, healthy subjects
would experience a range of muscle activity-dependent lymph flow
rates through the course of a day. Lymph flow was found to
increase 10 to 13-fold from basal night levels during normal daily
activities (steady-state standing/walking) [118,119], and could
peak to 5-fold of basal day levels at 1 h post-onset of exercise
(running/cycling) [64].
iii. Plasma Clearance. The plasma clearance rates (kCL,i n
units of s
21) or terminal half-lives (t=(ln 2)/kCL, in units of s) of
proteins used in this model (Table 4) represented the non-specific
physiological elimination processes that include kidney filtration,
liver conjugation, and proteolytic catabolism. Where possible, we
distinguished this type of clearance from the early plasma
clearance processes such as rapid uptake by various tissue organs
(biodistribution phase), which was represented separately in our
model by the extravasation of proteins into tissue compartments
(kP) with subsequent receptor-specific sequestration (kc, kon) and
internalization (kint). For VEGF in particular, we approximated
from Eppler et al.’s compartmental model that distinguished
between receptor-specific tissue uptake and non-specific
elimination components of plasma clearance [120]. Their fitted
Table 6. Transport Parameters – Lymphatic Flow Rates.
Tissue Compartment ‘‘Normal’’ ‘‘Calf’’ Unit Ref
Value Value
Lymphatically-drained tissue mass 50.02 0.92 kg
a,b
Basal Levels
Supine; Night/Asleep 2 (1.7–2.5) mL/h/(g SkM) [62]
kL/mass 5.6?10
27 cm
3/s/(g tissue)
c
kL 0.028 0.0005 cm
3/s
Supine; Day/Awake (Simulation Control) kL 0.14 0.0026 cm
3/s ,56asleep [118]
Active Levels
Steady Exercise kL 0.28 0.0051 cm
3/s ,26awake [64,119]
Peak Exercise kL 0.70 0.013 cm
3/s ,56awake [64]
Conversions are based on:
a the mass composition of a 70-kg man as 5-kg blood, ,14 kg non-lymphatically drained mass, ,51 kg lymphatically drained mass
[60,116,117].
bhealthy calf volume from Table 1 with 1.06 g/cm
3 [72,87].
cassuming all tissues to have the skeletal muscle lymph flow rate.
doi:10.1371/journal.pone.0005108.t006
Table 5. Transport Parameters: Surface Area Recruitment Factor for Effective Vascular Permeability Rates.
Surface Area Recruitment Factor, cj j=Normal (Rest of Body) j=Healthy Calf
Value Ref Value Ref
Supine (control) 1 basal 1 basal
Dependent 1 basal 0.375 VAR [112]
Exercise (leg) 1 basal 3 [113,114]
VAR=venoarterial reflex.
doi:10.1371/journal.pone.0005108.t005
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21 or
1.08610
23 s
21, corresponding to an effective clearance half-life of
,10.7 min. Synthetic soluble VEGF-traps that consisted of partial
extracellular domains of VEGFR1 (or VEGFR1 and VEGFR2)
fused to the Fc region of IgG1 (dimers) were found to have
clearance rates in the range of ,3t o8 610
26 s
21 [121,122]. Thus
for endogenous sVEGFR1 and VEGF-sVEGFR1, with no
documented clearance rates, we assumed a clearance rate of
5610
26 s
21.
3.4. Protein Expression Levels
i. Interstitial Matrix Binding Sites for VEGF and
sVEGFR1. Of the various types of glycosaminoglycans (GAGs)
present on proteoglycans, VEGF165 interacts predominantly with
heparin and heparan sulfates (HS), while considerably less with
chondroitin sulfate or dermatan sulfate [123]. As heparin is mostly
localized on mast cells [123], we derived our matrix-specific
VEGF-binding site densities from only HS-proteoglycans
(HSPGs), as summarized in Table 7. Other contributions to
VEGF-binding matrix sites from glycoproteins such as fibronectin
were ignored due to having concentrations 1–3 orders of
magnitude lower than HSPG contributions in the ECM and
BM [124]. Cell-surface HSPGs [125], as well as soluble-HSs,
soluble-fibronectins and platelets in the plasma [126,127], were
also not explicitly modeled.
In the ECM, the VEGF-binding matrix-site densities were
estimated from FGF-binding sites as in our previous models
[54,107]. In the BMs, we modeled the HSPG content of both
tissue compartments based on measurements from Engelbreth-
Holm-Swarm (EHS) sarcomas in control (non-diabetic) mice
[128]. EHS mouse tumors produce a homogenous interstitial
matrix of basement membrane material, making EHS interstitial
matrix a typical in vitro model for physiological BMs which are
usually too thin for content analysis [128,129]. To convert the
HSPG protein weights into molar concentrations, we assumed the
average HSPG to weigh 387 kDa – a sum of the 300 kDa protein
core weight (averaged over 470-kDa Perlecan [130], 250-kDa
Agrin [131], 180-kDa Collagen XVIII PG [131]) and ,3 HS-
chains (averaged 29 kDa [132]) per HSPG. To convert the HSPG
content into VEGF-binding site densities, we further assumed an
average of 4.2 VEGF-binding sites per HSPG, based on
experiments showing: ,3 HS-chains per HSPG [130,131];
,30% of HS-chains displaying no VEGF165 affinity [123]; $2
VEGF-binding sequences (‘‘SAS domains’’) present within each
HS-chain [123,125].
Due to insufficient literature data on the availability of
sVEGFR1-binding sites on HSPGs, we did not separately
calculate their corresponding densities and instead assumed that
sVEGFR1 would share (competitively) the same matrix sites with
VEGF.
Table 7. Total Interstitial VEGF/sVEGFR1-Binding Site Densities, Based on Matrix Heparan Sulfate Proteoglycans (HSPGs).
‘‘Normal’’ & ‘‘Calf’’ Tissue Compartments Value Unit Ref
ECM [Reference Tissue: Cultured endothelial cells]
[FGF-binding HS-sites]ECM 1.5?10
12 available sites/mm
2 ECM [166]
Simulation Control 0.75 mM [107]
[VEGF-binding HS-sites]ECM
Simulation Control 2.15?10
211 moles/cm
3 Normal tissue
[VEGF-binding HS-sites]ECM 8.24?10
211 moles/cm
3 Healthy Calf tissue
EBM/PBM [Reference Tissue: EHS sarcoma in control mice]
[HSPGs]IS,EHS 0.49 mg HSPG/g EHS tumor [128]
1.13 g HSPG/L of ISEHS
a
[HSPGs]BM,SkM 2.92 mmoles total HSPG/L of total BMSkM
b, c
[VEGF-binding HS-sites]BM 12.3 mmoles total binding sites/L of total BMSkM
d
21.2 mmoles available binding sites/L of available fluid in BMSkM
e
Simulation Control 20 mM
d
[VEGF-binding HS-sites]BM
Simulation Control 2?10
212 moles/cm
3 Normal tissue
[VEGF-binding HS-sites]EBM 4?10
212 moles/cm
3 Healthy Calf tissue
Simulation Control 2?10
211 moles/cm
3 Normal tissue
[VEGF-binding HS-sites]PBM 4.8?10
211 moles/cm
3 Healthy Calf tissue
EHS=Engelbreth-Holm-Swarm.
SkM=skeletal muscle. Conversions are based on:
a cell volume fraction of 0.57 in tumor tissue [83].
baverage 387-kDa HSPG [see text].
cthe IS of EHS tumors is homogenously BM [128].
d,4.2 VEGF-binding sites per HSPG.
e31% (available fluid/fluid volume)BM and 18% (available fluid/total volume)BM based on Table 1 geometry.
M in moles
 
cm3 tissue
     
~ M in moles=L ðÞ ½  | available fluid volume fraction ðÞ : L
 
1000 cm3   
ECM : 2:87, 10:98|10{5 moles
 
cm3 tissue
    
M ðÞ for normal and healthy calf respectively:
EBM : 1, 2|10{5 moles
 
cm3 tissue
    
M ðÞ for normal and healthy calf respectively:
PBM : 1, 2:4|10{6 moles
 
cm3 tissue
    
M ðÞ for normal and healthy calf respectively:
doi:10.1371/journal.pone.0005108.t007
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body’’ and ‘‘healthy calf’’ compartments, we converted the same
VEGFR1 and VEGFR2 protein measurements [133,134] from
human vastus lateralis muscles referenced in our previous models
[54] – using our new geometric properties (73 cm
2/cm
3 tissue) and
dimeric molecular weights of the VEGFRs – to get corresponding
density ranges of 60,000–68,000 VEGFR1 and 10,000–14,000
VEGFR2 per endothelial cell. NRP1 protein expression in vivo has
yet to be documented in literature. As before [54], we interpreted
these density ranges as upper bounds for our control values –
assumed at 10,000/EC for all VEGFRs – since the measurements
did not discriminate between intracellular vs. surface-bound vs.
soluble forms of the receptors. There was also evidence suggesting
VEGFR2 densities may actually be higher than VEGFR1 densities
[19,96–98]. Without definitive quantification, we assumed a 1:1:1
ratio of VEGFR1:VEGFR2:NRP1 densities at control. Converted
values are tabulated in Table 8.
iii. Interstitial Free VEGF and sVEGFR1. In healthy
humans at rest, the interstitial free VEGF concentration has
been measured in vastus lateralis microdialysates to be about 12–
50 pg/mL [135,136], which converts to 0.26–1.1 pM based on
46-kDa VEGF dimers. We thus targeted a range of 0.5–1.0 pM in
the ‘‘normal body’’ and ‘‘healthy calf’’ interstitia (Table 9). The
basal interstitial sVEGFR1 concentrations have not been reported
in the literature. We thus estimated a target range for interstitial
sVEGFR1 concentrations – by scaling the target range for
interstitial VEGF concentrations to the VEGF:sVEGFR1 protein
weight measurements in tibialis anterior (TA) homogenates in
normal mice [19] – at about 0.6–1.2 pM (Table 9). Limitations
were noted in extrapolating from homogenate measurements
that did not discriminate between interstitial and intracellular
proteins. Thus in the case that plasma and interstitial
concentrations could not be simultaneously modeled, we opted
to fit targeted ranges for plasma concentrations in violation of
the interstitial targets.
iv. Plasma Free VEGF and sVEGFR1. In healthy subjects,
measurements of plasma VEGF concentrations generally fell
within two ranges: 78–113 pg/mL plasma (,2 pM) [44–46] and
32–41 pg/mL plasma (,1 pM) [49,137,138]. We thus simulated
plasma VEGF at 1.5 pM as healthy control (Table 10).
Literature data on plasma sVEGFR1 concentrations were
significantly more heterogeneous [39,40,42–52]. In defining our
target ranges, we limited our sources to healthy control data from
PAD-specific studies, for consistency in data source compared to
our concurrent studies modeling PAD patients. Since most healthy
measurements from studies on other atherosclerotic vascular
diseases (e.g. coronary artery disease (CAD), diabetes with
atherosclerosis [44,52]) also supported the higher healthy control
range of 21–22 ng/mL as reported in PAD studies [44,45], we
simulated plasma sVEGFR1 at ,100 pM as healthy control
(Table 10), such that our ‘‘healthy subject’’ was defined within the
same control demographics typically considered in PAD/CAD/
diabetic studies.
4. Numerical Solutions & Computational Simulations
All simulations and data plots presented in this chapter were
performed on the numerical computing platform, MATLAB 7.3.0
R2006b (MathWorks, Natick, MA), and run on a desktop PC. The
Table 8. Total Surface Receptor Densities.
‘‘Normal’’ & ‘‘Calf’’ Tissue Compartments Value Unit Ref
VEGFR1
Experimental Measurement 1.6–1.8 pg/mg protein [133,134]
0.73–0.82 pmoles/cm
3 tissue
60,000–68,000 #/EC
Simulation Control 10,000 #/EC
1.21?10
213 ; moles/cm
3 Normal tissue ;
7.31?10
214 moles/cm
3 Healthy Calf tissue
VEGFR2
Experimental Measurement 0.33–0.5 pg/mg protein [133,134]
0.12–0.18 pmoles/cm
3 tissue
10,000–14,000 #/EC
Simulation Control 10,000 #/EC
1.21?10
213 ; moles/cm
3 Normal tissue ;
7.31?10
214 moles/cm
3 Healthy Calf tissue
NRP1
Experimental Measurement N/A
Simulation Control 10,000 #/EC
1.21?10
213 ; moles/cm
3 Normal tissue ;
7.31?10
214 moles/cm
3 Healthy Calf tissue
Experimental measurements from human vastus lateralis muscle. Conversions are based on 155 mg protein/g tissue [167], 1.06 g/cm
3 tissue [87] , 360-kDa VEGFR1
homodimers [103], 460-kDa VEGFR2 homodimers [103] and microvessel surface area densities (ESAV) from Table 1.
R in moles
 
cm3 tissue
     
~ R in #=EC ðÞ ½  |ESAV=ECSA= Avogadro0s # ðÞ
i:e: 12:1, 7:31|10{18 moles
 
cm3 tissue
    
#=EC ðÞ for normal and healthy calf respectively:
doi:10.1371/journal.pone.0005108.t008
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as an initial value problem to steady state using MATLAB’s
‘ode15s’ solver routine (a multi-step variable-order stiff problem
solver that employs the numerical differentiation formulas
scheme), with the relative error tolerance set at 10
26 (0.0001%
accuracy) and an initial step size of 10
24.
The following is an outline of the simulation experiments
performed and the organizational structure of the results section
below. Results section 1 covers the initial steps of finding the tissue
secretion rates necessary to reproduce a healthy control subject’s
expected ranges of interstitial and plasma concentrations of VEGF
and sVEGFR1 (Tables 9 and 10), with all other parameters
(geometry, kinetics, transport and protein expression) set at values
summarized for a supine healthy subject (Tables 3 to 8). At the
established control settings, a detailed molecular characterization
of the healthy model is then given: the steady-state compartmental
distributions of total VEGF and sVEGFR1; the tissue-specific
profiles of matrix site occupancies and receptor signaling; and the
balance of mass flows. Such characterization proved useful in
explaining VEGF/sVEGFR1 system responses observed in
subsequent parameter sensitivity analyses of: the secretion rates
of VEGF and sVEGFR1 (Results section 2); surface receptor
densities (section 3); VEGF-affinities of surface receptors (section
4); VEGF-affinities of interstitial matrix sites (section 5); and
transport parameters (section 6).
Results
1. Determining basal profiles for a healthy human subject
1.1. Targeting experimental plasma concentrations of
VEGF and sVEGFR1 as functions of their secretion rates
from the ‘‘normal’’ and ‘‘calf’’ compartments
In our stepwise search for the set of secretion rates that could
computationally replicate the interstitial and plasma concentra-
tions of VEGF and sVEGFR1 expected from experimental data in
our healthy control model, we first established the VEGF
Table 9. Steady-State Interstitial Concentrations of VEGF and sVEGFR1.
‘‘Normal’’ & ‘‘Calf’’ Tissue Compartments Value Unit Ref
[VEGF]IS
Reference Tissues Human VL microdialysate
Experimental Range 12–50.4 pg/mL [135,136]
0.26–1.1 pM
a
Simulation Target Range 0.5–1.0 pM
Achieved @ Healthy Ctrl 10 pM Fig. 4
[sR1]IS
Reference Tissues Calculated for human VL; Ratios from mice TA homogenates
Experimental Range Calculated from (sVEGFR1:VEGF) NC, baseline=120:21 pg/mg protein [19]
Simulation Target Range 0.6–1.2 pM
b
Achieved @ Healthy Ctrl 36 pM Fig. 4
Conversions are based on:
a 46-kDa VEGF-dimers [103].
b220-kDa sVEGFR1-homodimers.
doi:10.1371/journal.pone.0005108.t009
Table 10. Steady-State Plasma Concentrations of VEGF and sVEGFR1.
Blood Compartment Value Unit Ref
[VEGF]plasma
Experimental Range 1 (healthy controls in PAD studies) 78–113 pg/mL plasma [44–46]
Experimental Range 2 (resting controls in exercise studies) 32–41 pg/mL plasma [49,137,138]
Simulation Target Range 1–2 pM
a
Achieved @ Control 1.5 pM
[sR1]plasma
Experimental Range 1 (higher range of healthy controls in PAD studies) 21–22 ng/mL plasma [44–46]
Experimental Range 2 (lower range of healthy controls in PAD studies) 0.9 ng/mL plasma [43,46]
Simulation Target Range 100 pM
b from range 1
Achieved @ Control 100 pM
Conversions are based on:
a 46-kDa VEGF-dimers [103].
b220-kDa sVEGFR1-homodimers.
doi:10.1371/journal.pone.0005108.t010
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sVEGFR1 at modified secretion rates.
In the absence of sVEGFR1 expressions (qsR1=0), the steady-
state plasma and interstitial free VEGF concentrations ([V]pl, [V]IS)
were mapped out as functions of total VEGF-secretion rates from
the normal tissue and calf compartments (qTotalVEGF,Normal
and qTotalVEGF,Calf), where the individual isoforms VEGF121
and VEGF165 were secreted at a ratio of 1:10 (Fig. 2A: top
row, ‘-sR1’). Where [V]pl was within the experimental ranges of
1–2 pM, [V]IS were predicted to be ,10-fold higher, in
contradiction of microdialysis measurements of [V]IS at around
1 pM. Therefore, in the absence of sVEGFR1 expression, the
control VEGF-secretion rates necessary to achieve the targeted
[V]pl of 1.5 pM, as well as symmetric [V]IS (i.e., 15 pM in both
‘‘calf’’ and ‘‘normal’’ interstitia), would have been qV,-Ctrl=
(qTotalVEGF,Normal,q TotalVEGF,Calf)=(0.264, 0.154) molecules/
MD/s.
However, the incorporation of sVEGFR1 expression into the
system (Fig. 2A: ‘+sR1’) was found to shift the VEGF profile
upwards in the plasma – i.e., if VEGF-secretion rates were fixed at
qV,-Ctrl, [V]pl became 2.1 pM once sVEGFR1-secretion rates were
high enough to attain a target [sR1]pl of 100 pM. Hence in seeking
our control sVEGFR1-secretion rates, we redefined the control
VEGF-secretion rates to qV,+Ctrl=(q TotalVEGF,Normal,q TotalVEGF,Calf)
=(0.1925, 0.1155) molecule/MD/s=(9.3, 5.7)?10
218 mole/
(cm
3 tissue)/s, so that [V]pl would start off at the lower bound of
the target range (1 pM) in the absence of sVEGFR1. The steady-
state plasma and interstitial free sVEGFR1 concentrations
([sR1]pl, [sR1]IS) were then plotted over a range of sVEGFR1-
secretion rates from the normal tissue and calf compartments
(qsR1,Normal and qsR1,Calf) in Fig. 3A, while VEGF-secretion was
fixed at qV,+Ctrl. The control sVEGFR1-secretion rates that could
attain a [sR1]pl of 100 pM, as well as symmetric [sR1]IS (i.e,
36 pM in both ‘‘calf’’ and ‘‘normal’’ interstitia), were determined
to be qsR1,Ctrl=(q sR1, Normal,q sR1,Calf)=(0.0107,0.0210) mole-
cules/EC/s=(1.3, 1.5)?10
219 moles/(cm
3 tissue)/s. At this
qsR1,Ctrl,[ V ] pl became exactly the targeted 1.5 pM, with [V]IS
now at 10 pM (Fig. 2A: middle row). Although the control
secretion rates needed to reach a target set of [V]pl and [sR1]pl
were not unique – i.e., higher sVEGFR1-secretion rates could
theoretically also have elevated [V]pl from below 1 pM in absence
of sVEGFR1 to 1.5 pM in presence of sVEGFR1 – we settled on
this set of qV,+Ctrl and qsR1,Ctrl (Table 11) such that [V]pl remained
within experimental range, with or without sVEGFR1 expression
in the simulation.
1.2. Basal distribution profiles
Using the aforementioned control secretion rates, the following
molecular distributions and occupancy profiles were achieved at
steady state. (See ‘‘Healthy Ctrl’’ in Supplemental Fig. S1 for
details.)
i. VEGF distribution. The ratio of free VEGF121:VEGF165
in plasma and interstitial concentrations were 1:10.8 and 1:10.6
respectively (Fig. S1-A), just slightly lower than the original isoform
ratio of the VEGF-secretion rate (1:10). In the blood, both
VEGF121 and VEGF165 were 23% free and 77% bound to
sVEGFR1 (Fig. S1-C,D). This predicted complexed fraction of
VEGF was much higher than that experimentally measured by
Belgore et al. in healthy human plasma (,4% mole fraction, based
on 113 pg/mL free VEGF and 18 pg/mL complexed sVEGFR1)
[45]. In the normal interstitium, VEGF121:VEGF165 were
0.9%:0.6% free, 0.8%:0.6% sVEGFR1-bound, 98.3%:63.0%
surface receptor-bound, and 0%:35.8% matrix-bound (Fig. S1-
C,D). In the calf interstitium, VEGF121:VEGF165 were 4.8%:1.4%
free, 5.0%:1.5% sVEGFR1-bound, 90.2%:24.7% surface
receptor-bound, and 0%:72.4% matrix-bound (Fig. S1-C,D). In
other words, while VEGF was mostly bound to sVEGFR1 in
blood, almost all extracellular VEGF in muscle tissue was surface
receptor- or matrix-bound. Compared to our previous single-
compartment and multi-compartment results in the absence of
sVEGFR1 [54,59], the addition of sVEGFR1 into the VEGF
system did not significantly alter the predicted total VEGF
distribution in normal muscle tissue.
ii. sVEGFR1 distribution. In the blood, 95% of total
sVEGFR1 were free, with only 5% complexed to VEGF (Fig.
S1-B). This predicted VEGF-occupancy of total plasma sVEGFR1
was again higher than that experimentally measured in healthy
human plasma (,0.65% mole fraction, based on 21 ng/mL free
sVEGFR1 vs. 18 pg/mL complexed sVEGFR1) [45]. In the
normal:calf interstitium, sVEGFR1 were 1.6%:1.9% free, 97.4%
matrix-bound, 0.4%:0.6% VEGF-bound (with or without NRP1
coupling), and 0.6%:0.1% NRP1-bound.
iii. Inter-compartmental distributions. Due to
geometrical differences between histological cross-sections of
vastus lateralis and gastrocnemius, our normal muscle was
characterized with higher total receptor density (due to 11.3%
higher myocyte volume fraction, Table 1) than that in calf
muscle, while our calf muscle was characterized with higher total
matrix site density (due to 8% larger available interstitial fluid
volume fraction, Table 1) than that in normal muscle. Therefore
the normal compartment had higher amount of total
extracellular VEGF121 (mostly surface receptor-bound), but
lower amounts of total extracellular VEGF165 and sVEGFR1
(mostly matrix-bound), per tissue volume than the calf
compartment (Fig. S1-B,C,D).
iv. Occupancy of matrix sites. The fractional occupancies
of total matrix sites were uniformly minute across ECM, EBM and
PBM, as well as between normal and calf compartments
(differences ,0.001%) – only 0.04% VEGF165-occupied and
0.15% sVEGFR1-occupied – leaving 99.81% unoccupied (Fig. S1-
E,F,G). These fractional occupancies remained characteristically
low (,0.6%) throughout sensitivity analyses.
v. Occupancy of VEGFRs and NRP1. The fractional
occupancies of total surface receptors were also consistent
between normal and calf compartments (differences ,1%): (i)
total VEGFR1 were 26% free, 66% NRP1-coupled but not
VEGF-ligated, and 8% VEGF-ligated (Fig. S1-H); (ii) total
VEGFR2 were 80% free and 20% VEGF-ligated (Fig. S1-I); (iii)
total NRP1 were 16% free, 0.3% sVEGFR1-bound with or
without VEGF121, 0.1% VEGF165-bound, 66% coupled to
unactivated VEGFR1 (i.e., VEGFR1-NRP1), and 18% coupled
to signaling VEGFRs (i.e., VEGF121-VEGFR1-NRP1 or
VEGFR2-VEGF165-NRP1) (Fig. S1-J).
1.3. Physiological variation in calf volume-of-interest
Within a threefold increase in volume of the ‘‘healthy calf
muscle’’ compartment (up to 2,604 cm
3), along with correspond-
ing decreases in the ‘‘normal compartment’’ volume (down to
58,717 cm
3), all control predictions of VEGF and sVEGFR1
distributions remained consistent (to within 1%), while receptor
occupancy profiles remain unchanged. This implied that in cases
that require modeling of bigger calf regions-of-interest, such as to
include the tibialis anterior, or to study bilateral calves, the
geometric differences between our calf vs. normal muscle
parameterizations would not cause deviations in the overall
baseline healthy profile attained by the stated set of control
secretion rates.
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PLoS ONE | www.plosone.org 17 April 2009 | Volume 4 | Issue 4 | e5108Figure 2. Targeting Control VEGF-Secretion Rates (qTotalVEGF) for Basal Profile of Healthy Subject. A. Steady-state sensitivity of plasma
and interstitial concentrations of free VEGF (top and middle rows) and free sVEGFR1 (bottom row) to qTotalVEGF from normal tissue (y-axis) and calf (x-axis.
VEGF isoforms were secreted at a ratio of VEGF121:VEGF165=1:10. Top/middle row: In absence of sVEGFR1 (qsR1=0; labelled ‘-sR1’), plasma free VEGF
reached the targeted 1.5 pM at the control VEGF-secretion rates of qV,-Ctrl=(q TotalVEGF,Normal,q TotalVEGF,Calf)=(0.264,0.154) molecule/MD/s. The
incorporation of sVEGFR1 expression (qsR1=q sR1,Ctrl; labelled ‘+sR1’) raised plasma VEGF significantly (red arrow) but with negligible effects on
interstitial VEGF. To keep plasma free VEGF at the targeted 1.5 pM, the control VEGF-secretion rates were redefined (green arrow) to be
qV,+Ctrl=(q TotalVEGF,Normal,q TotalVEGF,Calf)=(0.1925,0.1155) molecule/MD/s. Grey and beige spheres mark the interstitial and plasma VEGF levels reached
at qV,-Ctrl and qV,+Ctrl respectively. Bottom row: Despite sVEGFR1’s role as a VEGF sink, free sVEGFR1 only changed inversely relative to free VEGF
changes in the calf interstitum in the direction of increasing qTotalVEGF,Calf. Orange/black arrows indicate inverse/direct relation between sVEGFR1
concentrations and VEGF-secretion rates. B. Density of VEGF-VEGFR complexes changed in proportion to interstitial free VEGF levels with increasing
qTotalVEGF. Bracketed percentages are VEGF-bound fractional occupancies of total VEGFR, averaged (range,0.3%) between normal and calf
compartments. In figure: ‘+’=control; ‘max’ and ‘min’ bound targeted ranges; ‘MD’=myonuclear domain; ‘V121’=VEGF121; ‘V165’=VEGF165;
‘R1’=VEGFR1; ‘sR1’=sVEGFR1; ‘R2’=VEGFR2.
doi:10.1371/journal.pone.0005108.g002
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Fig. 4 summarizes the inter- and intra-compartmental flow
balance of soluble species at basal secretion rates; as will be shown
in subsequent sections, the net directions and relative magnitudes
of these mass flows dictated how the system responded to
parameter perturbations. A key difference was noted between
the VEGF and sVEGFR1 flows at steady state: most interstitial
VEGF was internalized locally, via complex formation with
abluminal VEGFRs, before it had a chance to permeate into the
plasma, contributing to its lower plasma concentrations; whereas
interstitial sVEGFR1, apart from its abluminal internalization,
had an equally significant route of escape via lymph flow which
contributed to its higher plasma concentration. Consequently, the
transendothelial (plasma vs. interstitial) concentration gradients
were differentially established, such that free VEGF and
sVEGFR1-VEGF complexes experienced net intravastion (IS to
plasma) at control, while free sVEGFR1 had an overall tendency
to extravasate (plasma to IS) at control. Integral to the flow
balances were the net mass transfers between the three soluble
species: interstitially, the steady-state inflows for both free VEGF
and sVEGFR1 outweighed their respective outflows, signifying a
net tendency for them to associate and form sVEGFR1-VEGF
complexes; in the plasma, the steady-state inflows for VEGF and
sVEGFR1 were less than their respective outflows, indicative of an
additional source from net dissociation of sVEGFR1-VEGF
complexes.
Figure 3. Targeting Control sVEGFR1-Secretion Rates (qsR1) for Basal Profile of Healthy Subject. A: Steady-state sensitivity of
plasma and interstitial concentrations of free VEGF (top row) and free sVEGFR1 (bottom row) to qsR1 from normal tissue (y-axis) and calf (x-
axis). Top row: Interstitial free VEGF decreased while plasma free VEGF increased with increasing qsR1. Blue/black arrows indicate inverse/direct
relation between VEGF concentrations and sVEGFR1-secretion rates. Bottom Row: The targeted 100 pM of free sVEGFR1 was reached in
plasma at the control secretion rates of qsR1,Ctrl=(q sR1,Normal,q sR1,Calf)=(0.0107,0.0210) molecule/EC/s. Beige spheres mark the interstitial and
plasma sVEGFR1 levels reached at qsR1,Ctrl. B: Density of VEGF-VEGFR complexes were insensitive to qsR1. Bracketed percentages are VEGF-
bound fractional occupancies of total VEGFR, averaged (range,0.4%) between normal and calf compartments. In figure: ‘+’=control; ‘max’,
‘min’ and ‘mean’ indicate targeted ranges; ‘EC’=endothelial cell; ‘V121’=VEGF121; ‘V165’=VEGF165; ‘R1’=VEGFR1; ‘sR1’=sVEGFR1; ‘R2’=
VEGFR2.
doi:10.1371/journal.pone.0005108.g003
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systemically lower free sVEGFR1 or free VEGF
concentrations respectively
2.1. System sensitivity to VEGF-secretion rates
First we examined the VEGF response to increasing VEGF-
secretion rates as illustrated in Fig. 2A. [V]IS,Normal and [V]IS,Calf
were essentially determined by their respective local VEGF
secretion rates, qTotalVEGF,Normal and qTotalVEGF,Calf. This was
expected with [V]IS, since the intracompartmental flows (secretion
and internalization) of VEGF dominated over its intercompart-
mental flows (vascular permeability and lymphatic drainage) in
magnitude (Fig. 4). Thus [V]IS was greatly sensitive to local
changes in qTotalVEGF, but relatively insensitive to qTotalVEGF of the
other compartment due to weak intercompartmental communi-
cation. Similarly, [V]pl was increasingly dependent on qTotalVEGF,-
Normal but largely insensitive to qTotalVEGF,Calf, following the much
larger intravasation flow from the normal compartment relative to
that from the calf (Fig. 4).
Table 11. VEGF- and sVEGFR1-Secretion Rates (Fitted Kinetic Parameters).
Normal Healthy Calf Units
Secretion of VEGF from PCs into IS
qV121:qV165 1:10 1:10
qV121 0.0175 0.0105 molecule/MD/s
8.44?10
219 5.21?10
219 mole/(cm
3 tissue)/s
qV165 0.175 0.105 molecule/MD/s
8.44?10
218 2.73?10
218 mole/(cm
3 tissue)/s
Secretion of sVEGFR1 from ECs into IS
qsR1 0.0107 0.021 molecule/EC/s
1.30?10
219 1.53?10
219 mole/(cm
3 tissue)/s
MD=myonuclear domain (parenchymal cell unit).
EC=endothelial cells.
IS=interstitial space.
Conversions are based on geometry parameters from Table 1:
qVEGF in moles
 
cm3 tissue
    
sec
     
~ qVEGF in molecules=MD=sec ðÞ ½  = Avogadro0s # ðÞ =MDSA|FSAV
i:e: 4:82, 4:96|10{17 moles
 
cm3 tissue
    
sec
    
molecules=MD=sec ðÞ for Normal and Healthy Calf respectively:
qsR1 in moles
 
cm3 tissue
    
sec
     
~ qsR1 in molecules=EC=sec ðÞ ½  = Avogadro0s # ðÞ =ECSA|ESAV
i:e: 12:1, 7:31|10{18 moles
 
cm3 tissue
    
sec
    
molecules=EC=sec ðÞ for Normal and Healthy Calf respectively:
doi:10.1371/journal.pone.0005108.t011
Figure 4. Basal Steady-State Flow Profiles of Free VEGF (left), sVEGFR1-VEGF Complexes (middle), Free sVEGFR1 (right). Solid-colored
arrows represent intra-compartmental flows (i.e., secretion, internalization) and inter-compartmental flows (i.e., net vascular permeability, lymph flow,
plasma clearance), with their relative magnitudes reflected by arrow widths. Color-graded arrows between columns indicate mass transfer flows
between species (i.e., net association of free VEGF and free sVEGFR1 to form sVEGFR1-VEGF complexes, or net dissociation of the complex back into
its constituents).
doi:10.1371/journal.pone.0005108.g004
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by VEGF-secretion rates in two asymmetrical ways. Firstly, the
response to increasing qTotalVEGF,Calf was expected from
previous flow analysis (Fig. 4): a surge in [V]IS,Calf was
compensated by increased complex formation, lowering
[sR1]IS,Calf in the process of association (Fig. 2A). Subsequent
intravasation of sVEGFR1-VEGF complexes and their dissoci-
a t i o ni np l a s m aw a st o om o d e s tt oa f f e c t[ s R 1 ] pl or [sR1]IS,Normal.
A second mode of response occurred with increasing qTotal-
VEGF,Normal, beginning with an elevated [V]IS,Normal which
promoted VEGFR2-VEGF165-NRP1 formation, thereby dimin-
ishing the availability of free NRP1 to bind free sVEGFR1. As a
result of decreased sVEGFR1-internalization via NRP1-com-
plexes, interstitial free sVEGFR1 actually increased globally (in
both [sR1]IS,Normal and [sR1]IS,Calf)v i a[ s R 1 ] pl (Fig. 2A). The
asymmetry was a consequence of the calf compartment having
less endothelial surface area per volume and thus lower total
surface receptor densities than the normal muscle compartment
(supplemental Fig. S1), such that the second mechanism
involving NRP1-VEGFR2 coupling was not sizeable enough
to override the first mechanism involving sVEGFR1-VEGF
association.
Lastly, the density of VEGF-ligated signaling complexes on the
abluminal surface of the endothelium positively correlated with
[V]IS. Consequently, increasing qTotalVEGF intensified both
VEGFR1 and VEGFR2 signaling profiles (Fig. 2B).
2.2. System sensitivity to sVEGFR1-secretion rates
Fig. 3A illustrates the VEGF and sVEGFR1 responses to
increasing sVEGFR1-secretion rates. [sR1]IS,Normal and [sR1]IS,-
Calf were predicted to most significantly depend on their local
sVEGFR1-secretion rates, qsR1,Normal and qsR1,Calf respectively,
in a linear fashion. Flow analysis (Fig. 4) suggested that the
elevated interstitial free sVEGFR1 would then associate with
free VEGF to form sVEGFR1-VEGF complexes, which
accounted for the slight decreases in [V]IS in the direction of
increasing local qsR1. Furthermore, the complexes formed in the
interstitium were expected to intravasate and dissociate in the
plasma, as confirmed by the rise in [V]pl and [sR1]pl in the
direction of increasing qsR1,Normal. The cycle completes with
part of the elevated [sR1]pl extravasating back into the
interstitium, hence accounting for the increase in [sR1]IS,Calf
in the direction of increasing qsR1,Normal. Thus unlike VEGF in
the previous subsection, interstitial sVEGFR1 (e.g., [sR1]IS,Calf)
was able to respond to distal changes (e.g., qsR1,Normal). The
asymmetry where increasing qsR1,Calf did not elevate [sR1]IS,-
Normal was due to the fact that the intravasation flow of the
complex from the calf was insufficient to elevate [sR1]pl on its
own. Finally, the signaling profiles did not change significantly
as a function of qsR1 (Fig 3B), reflective of the minute changes in
[V]IS already described.
3. Receptor densities and ratios affected plasma and
interstitial concentrations of VEGF and sVEGFR1, as well
as surface-bound VEGFR occupancy
Receptor densities and ratios were varied over two orders of
magnitude about the healthy control values, while keeping VEGF-
and sVEGFR1-secretion rates fixed, in a steady-state sensitivity
analysis to predict system response to physiological/pathological
regulation of receptor expression levels. Interstitial and plasma
concentrations of free VEGF and free sVEGFR1 were found to be
sensitive over most of the tested ranges (Fig. 5A), as described in
further mechanistic detail below. Overall, increasing NRP1
density, increasing VEGFR2:VEGFR1 ratio (denoted as [R2]/
[R1]), and decreasing total VEGFR density all steepened plasma
vs. interstitium gradients (i.e., farther from 1:1) for VEGF
concentrations; while increases in all three parameters reduced
sVEGFR1 gradients (i.e., closer to 1:1). In addition, higher NRP1
density or [R2]/[R1] favored a net shift towards pro-angiogenic
signaling; while total VEGFR densities within the same order of
magnitude as NRP1 density were predicted to be optimal for
overall pro-angiogenic signaling (Fig. 5B–D).
3.1. Sensitivity to neuropilin-1 density
Higher NRP1 densities were generally associated with lower
concentrations of all soluble species, since NRP1 was a vehicle for
internalizing VEGF and sVEGFR1 via endothelial VEGF121-
NRP1, VEGF165-NRP1, sVEGFR1-NRP1, VEGF121-VEGFR1-
NRP1 complexes. For free VEGF, this was most evident at low
total VEGFR density (Fig. 5A), when the alternative internaliza-
tion route for VEGF via VEGFR was minimized. For free
sVEGFR1, this was most evident at high total VEGFR density
(Fig. 5A), when free VEGF remained low to reduce the secondary
effects of sVEGFR1-VEGF complex formation. Secondarily,
declines in sVEGFR1-VEGF complex concentrations followed
increases in NRP1 density (Fig. 5A), as NRP1 competed with
sVEGFR1 for binding with free VEGF.
Moreover, increasing NRP1 density shifted the VEGF-signaling
profiles as shown in Fig. 5B. The overall drop in ‘‘anti-angiogenic
potential’’, as represented by ligated VEGFR1 complexes, can be
explained by NRP1’s high affinity for VEGFR1. At 10
5 NRP1/EC,
almost all (97%) VEGFR1 became part of unligated VEGFR1-
NRP1 complexes – a shift that dramatically reduced the availability
of VEGFR1 for VEGF165-ligation (Fig. 5B). On the other hand, the
overall rise in ‘‘pro-angiogenic potential’’, as represented by ligated
VEGFR2 complexes, can be explained by NRP1’s role as a co-
receptor in presenting NRP1-bound VEGF165 to VEGFR2, as well
as in stabilizing VEGF165-VEGFR2 through their triplet configu-
ration. All together, these synergistic functions of NRP1 in reducing
anti-angiogenic complexes and promoting pro-angiogenic com-
plexes, were in tune with computational predictions from our
previous studies in the absence of sVEGFR1 [54].
3.2. Sensitivity to VEGFR2:VEGFR1 density ratio ([R2]/[R1])
Although higher NRP1 density in general lowered free VEGF
concentrations predominantly through enhanced internalization of
VEGF-bound NRP1, exceptions were noted in the region of low
[R2]/[R1] (,1), roughly between 10,000 to 20,000 total
VEGFR/EC, where free VEGF concentrations were apparently
higher at 10,000 NRP1/EC than at 1,000 NRP1/EC (Fig. 5A). In
this region, the greater abundance of VEGFR1 gave more
prominence to NRP1’s tendency to competitively shift the
distribution of total VEGFR1 towards formation of unligated
VEGFR1-NRP1 complexes, in the process freeing VEGF that had
been bound to uncoupled VEGFR1, hence elevating free VEGF
concentrations.
For the independent increase of [R2]/[R1] while fixing total
receptors at control densities, the following concentration changes
were observed in all three fluid compartments (Fig. 5A),
originating from the tissues’ interstitial fluids and propagated into
the plasma: (i) free VEGF121 increased – due to a net decrease in
internalization force (reduction in VEGF121-VEGFR1 and
VEGF121-VEGFR1-NRP1 outweighed increase in VEGF121-
VEGFR2) (Fig. 5C); (ii) free VEGF165 decreased – due to a net
increase in internalization force (increase in VEGF165-VEGFR2
and VEGFR2-VEGF165-NRP1 overshadowed reduction in
VEGF165-VEGFR1) (Fig. 5C); (iii) an overall decrease in free
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PLoS ONE | www.plosone.org 21 April 2009 | Volume 4 | Issue 4 | e5108Figure 5. Steady-State Sensitivity to Receptor Density. A. Sensitivity of plasma and interstitial concentrations of free VEGF, free sR1, and sR1-
VEGF complex to NRP1 density (3 surfaces), VEGFR1:VEGFR2 density ratio (x-axis), and total VEGFR density (y-axis). B–D. Sensitivity of signaling
complex distribution to NRP1 density (B), ratio of VEGFR2:VEGFR1 density ratio (C), and total VEGFR density (D). Bracketed percentages are VEGF-
bound fractional occupancies of total VEGFR1 (left) and total VEGFR2 (right), averaged (range ,0.9%) between normal and calf compartments. E.
Sensitivity of NRP1 distribution to total VEGFR density. ‘+’=control; ‘max’ and ‘min’ bound targeted ranges; ‘EC’=endothelial cell; ‘V121’=VEGF121;
‘V165’=VEGF165; ‘R1’=VEGFR1; ‘sR1’=sVEGFR1; ‘R2’=VEGFR2.
doi:10.1371/journal.pone.0005108.g005
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VEGF121:VEGF165=1:3 at [R2]/[R1]=10); and (iv) free
sVEGFR1 decreased – due to dissociation of NRP1 from
VEGFR1-NRP1 complexes to become available for sVEGFR1-
binding and internalization (data not shown).
3.3. Sensitivity to total VEGFR density ([R1]+[R2])
Our simulations presented several theoretical indications that
the VEGF/sVEGFR1 system has optimal operating range around
the VEGFR1:VEGFR2:NRP1 receptor density ratio of 1:1:1.
Firstly, in examining the free sVEGFR1 concentration surfaces
shown in Fig. 5A, the region of maximal or linear gain for each
surface always spanned total VEGFR densities near the same
order of magnitude as NRP1 density. In fact, the sVEGFR1
concentration surfaces for 10,000 NRP1/EC were not only
sigmoidal over the examined total VEGFR density range, centered
about [R1]+[R2]=20,000/EC, they were also sigmoidal in the
direction of VEGFR ratio, centered about 1:1. Similarly, of the
free VEGF concentration surfaces, the sigmoidal surface for
10,000 NRP/EC had the closest operating range over
[R1]+[R2]=20,000/EC. A second indication was based on the
observation that the formation of signaling VEGFR2 complexes
was biphasic in the direction of total VEGFR density, allowing the
most efficient net ‘‘pro-angiogenic potential’’ to be reached within
the order of 10,000 total VEGFR/EC (Fig. 5D).
Mechanistically, the dependence of signaling profiles on total
VEGFR density as depicted in Fig. 5D could be explained by two
forces: (1) the direct effects of the sheer increase in number of
VEGFRs available for VEGF ligation; (2) the indirect effects of
VEGFR’s density ratio relative to NRP1 which was fixed at
10,000/EC. The former effects increased quantities of non-NRP1-
coupled VEGF-VEGFR complexes with increasing total VEGFR
density, despite the diminishing fractional occupancies of VEGFRs
(Fig. 5D). The latter effects stemmed from an increasing
proportion of total NRP1 being used up in formation of unligated
VEGFR1-NRP1 complexes with increasing total VEGFR density
(Fig. 5E). This meant that the higher the total VEGFR density, the
less free NRP1 were available to form VEGFR2-VEGF165-NRP1
and VEGF121-VEGFR1-NRP1, hence the generally decreasing
contribution of these species in their respective signaling profiles
(Fig. 5D). The opposing trend in the biphasic nature of VEGFR2-
VEGF165-NRP1 (Fig. 5D) came from the fact that at very low total
VEGFR density, quantities of VEGFR2 were so limited that there
was an unusual population of VEGF165-NRP1 left at steady state
for 2,000 VEGFR/EC (Fig. 5E) with no VEGFR2 to present to.
Thus explained the quick jump in VEGFR2-VEGF165-NRP1 as
soon as VEGFR2 were available at 10,000 VEGFR/EC
(Fig. 5D,E).
4. VEGFRs’ affinities for VEGF affected free sVEGFR1
concentrations via NRP1 availability; NRP1’s affinity for
VEGF121 was inconsequential
This section explores system sensitivity to the effective
(microenvironment-dependent) dissociation constants of VEGF
from its receptors over the wide ranges reported in literature.
4.1. Sensitivity to VEGF-binding affinity of VEGFR1 and
VEGFR2
The shifts in signaling profiles were as expected from the
competitive binding of VEGF between VEGFRs: increasing one
VEGFR’s VEGF-affinity boosted formation of its signaling
complexes to the detriment of the other VEGFR’s complex
formation (Fig. 6A). As for the soluble species, total free VEGF in
all compartments decreased with increasing VEGF-binding
affinity of either VEGFR1 or VEGFR2 – presumably through
enhanced internalization of complexed VEGF (Fig. 6B). Free
sVEGFR1 concentrations, however, changed in opposite direc-
tions: lowered with increasing VEGF-VEGFR1 affinity but rose
with increasing VEGF-VEGFR2 affinity. The directional change
in free sVEGFR1 thus followed that of VEGFR2-VEGF165-NRP1
complexes (Fig. 6A) – i.e., the more VEGFR2-VEGF165-NRP1
complexes formed, the less unbound NRP1 available for binding
and internalization of free sVEGFR1 (Fig. 6C).
4.2. Sensitivity to VEGF-binding affinity of NRP1
Lowering NRP1’s affinity for VEGF165 over two orders of
magnitude – Kd(V165,N) from 200 pM to 25 nM –caused only
opposing changes of up to 0.3% in the VEGF-bound fractional
occupancies of VEGFR1 and VEGFR2 (Fig. 6D). The minute
attenuation of pro-angiogenic potential reflected a declining
availability of VEGF165-bound NRP1s for coupling with
VEGFR2, hence the diminishing quantities of VEGFR2-
VEGF165-NRP1 (Fig. 6D). Simultaneously in all fluid volumes,
free VEGF121 levels remained consistent while free VEGF165,
presumably released from NRP1s, elevated slightly (plasma data
shown in Fig. 6E). This in turn increased availability of free
VEGF165 for direct VEGFR1-binding (Fig. 6D).
Our simulations also predicted inconsequential effects from
incorporating the newly purported binding interaction between
NRP1 and VEGF121. Specifically, when modeling both VEGF121-
and VEGF165-affinities of NRP1 at the low affinities cited by Pan
et al. (220 nM and 120 nM respectively [105]), there were no
remarkable changes in signaling profiles (Fig. 6D) nor concentra-
tions of free soluble species (Fig. 6E) compared to simulation
results with no VEGF121-NRP1 binding but weak VEGF165-
NRP1 binding. Furthermore, when keeping VEGF165-NRP1
affinity at control (320 pM) and introducing VEGF121-NRP1
binding at an affinity 1.836higher than that (in accordance with
the ratio reported by Pan et al.), all system distributions were
almost identical to those at control – because even then, the
steady-state population of VEGF121-NRP1 only represented an
insignificant 0.7% of total VEGF121 in muscle tissues.
Thus, as long as VEGF had a lower affinity to NRP1 than to
VEGFRs, the system was largely insensitive to variations in the
VEGF-binding affinities of NRP1. This suggested that mechanis-
tically, the significance of NRP1 as a co-receptor in the VEGF
system could be largely attributed to NRP1’s strength in coupling
VEGFRs rather than its direct affinity for VEGF.
5. Densities and VEGF-affinity of interstitial matrix sites
affected only matrix-bound reservoirs of VEGF165 and
sVEGFR1
Steady-state analyses showed that fluctuations in the VEGF-
binding affinity and densities of interstitial matrix sites had no
detectable effects on the concentrations of all soluble species (in
both plasma and interstitial fluid), nor on surface receptor
occupancies (Fig. 7). In contrast, the quantities of matrix-bound
VEGF165 and sVEGFR1 increased drastically with increasing
matrix site densities (Fig. 7A,B); while the matrix-bound reservoir
of VEGF165 also grew drastically with higher VEGF165-affinity of
matrix sites (Fig. 7A). Whereas these effects culminated into
several-fold changes in total VEGF165 and sVEGFR1 in muscle
tissues, the fractional occupancy of total matrix sites remained very
low (at a consistent 0.19% irrespective of matrix site densities) and
changing minutely with varying VEGF165-affinity (up to 0.55% at
106control Kd(M,V165).
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PLoS ONE | www.plosone.org 23 April 2009 | Volume 4 | Issue 4 | e5108Figure 6. Steady-State Sensitivity to VEGF-Binding Affinities of Cell Surface Receptors: VEGFR1, VEGFR2 and NRP1. A. Higher VEGF-
VEGFR1 affinity and VEGF-VEGFR2 affinity respectively shifted the signaling profile towards anti- and pro-angiogenic complexes. B. Free VEGF levels
lowered with increasing VEGF-binding affinity of either VEGFR1 or VEGFR2; while free sVEGFR1 levels rose and fell with increasing VEGF-VEGFR1 and
VEGF-VEGFR2 affinity respectively. C. Availability of unbound NRP1 changed inversely with the amount of VEGFR2-VEGF165-NRP1 formed. Free VEGF
and sVEGFR1 levels (D), as well as signaling profiles (E), were largely insensitive to NRP1’s direct binding-affinity with VEGF. Bracketed percentages in
A and D are VEGF-bound fractional occupancies of total VEGFR, averaged (range ,0.3%) between normal and calf compartments. ‘+’/‘Ctrl’=control;
‘Kd(V,R)’=dissociation constant between VEGF and VEGFR; ‘Kd(V121/V165,N)’=dissociation constants between VEGF121/VEGF165 and NRP1;
‘R1’=VEGFR1; ‘sR1’=sVEGFR1; ‘R2’=VEGFR2.
doi:10.1371/journal.pone.0005108.g006
Figure 7. Sensitivity to Density & VEGF-Binding Affinity of Interstitial Matrix Sites for VEGF165 & sVEGFR1. Steady-state sensitivity of
VEGF165 (A) and sVEGFR1 (B) distributions in blood (top), normal tissue (middle) and calf tissue (bottom) compartments to the VEGF165-binding
affinity (Kd(M,V)) and densities ([ECM]; [BM]) of interstitial matrix sites. At control: Kd(M,V)=23.8 nM; [ECM]=20 mM; [BM]=0.75 mM. Concentrations of
soluble species (e.g., free VEGF165, free sVEGFR1, sVEGFR1-VEGF165) and surface VEGFR occupancies (e.g., VEGF165-VEGFR1, VEGF165-VEGFR2, VEGFR2-
VEGF165-NRP1) were completely insensitive; whereas the sizes of matrix-bound reservoirs of VEGF165 and sVEGFR1 (e.g., VEGF165-ECM, sVEGFR1-PBM)
were greatly affected. ‘Kd(M,V)’=dissociation constant between interstitial matrix sites and VEGF165; ‘[ECM]’ and ‘[BM]’=densities of binding sites for
VEGF or sVEGFR1 in extracellular matrix and basement membranes respectively’; ‘Ctrl’=control; ‘PBM’=parenchymal BM; ‘EBM’=endothelial BM;
V165=VEGF165; ‘R1’=VEGFR1; ‘sR1’=sVEGFR1; ‘R2’=VEGFR2.
doi:10.1371/journal.pone.0005108.g007
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plasma VEGF, plasma sVEGFR1 and interstitial sVEGFR1,
but not surface-bound VEGFR occupancy
Transport parameters were independently varied over two
orders of magnitude about control for sensitivity analysis. In
plasma, steady-state concentrations of all soluble species were
strongly dependent on transport rates, whereas in the interstitium,
sVEGFR1 concentration was much more sensitive than VEGF to
transport parameters. In general: increasing kP reduced plasma vs.
interstitium gradients (i.e., closer to 1:1) for both VEGF and
sVEGFR1 concentrations (Fig. 8A); increasing kL lessened VEGF
gradients but steepened sVEGFR1 gradients (Fig. 9A); while
decreasing kCL reduced VEGF gradients without much effect on
sVEGFR1 gradients (Fig. 10). Additionally, the current model
showed that physiological fluctuations in transport parameters
were ineffective in altering endothelial VEGFR occupancy, given
their minute effect on interstitial free VEGF levels.
6.1. Steady-state effects of vascular permeability rates (kP)
The effect of kP on free VEGF and sVEGFR1 concentrations
(Fig. 8A) could be explained by their associated flow changes
(Fig. 8B). Firstly, since the transendothelial VEGF gradient at
control favored net intravasation, increasing kP resulted in
significantly higher plasma concentrations of free VEGF. Intersti-
tially, the corresponding decreases in free VEGF were insignifi-
cant, as the change in VEGF’s transvascular flow was still
overshadowed in magnitude by its secretion and internalization
flows. Secondly, the transendothelial gradient of sVEGFR1 at
control favored net extravasation, hence increasing kP resulted in:
lower plasma concentrations of free sVEGFR1; as well as
increased free sVEGFR1 in the interstitium facing the endothe-
lium where kP was upregulated, at the expense of a decrease in
interstitial free sVEGFR1 in the other tissue compartment (e.g.,
‘‘Control’’ vs. ‘‘Fenestration’’ in Fig. 8).
VEGF and sVEGFR1 distribution changes were also more
drastic in blood than in interstitia. In the blood, the number of
complexed sVEGFR1-VEGF increased slightly (e.g., 1.56 from
control) with increasing global kP (e.g., 106 from control). This
was sufficient to elevate the fractional occupancy of total
sVEGFR1 (e.g., +9%) despite decreasing free sVEGFR1; yet not
enough to prevent overall reductions in bound fraction of total
VEGF (e.g., -14%) because of the greater increase in free VEGF.
In the interstitium, the fractional occupancies of VEGFR1 and
VEGFR2 by VEGF decreased ,0.5% within the 100-fold
increase in kP tested.
6.2. Steady-state effects of lymph flow rates (kL)
Similarly, kL-driven changes in steady-state concentrations of
free VEGF and sVEGFR1 (Fig. 9A) could be explained by their
associated flow changes (Fig. 9B). Since lymph flow represented a
unidirectional flushing of VEGF and sVEGFR1 from the
interstitium into blood, increasing kL resulted in higher plasma
and lower interstitial concentrations of free VEGF and sVEGFR1.
All resulting differences were significant except for interstitial free
VEGF, as lymphatic flow was also dwarfed by the secretion and
internalization flows in the net balancing of VEGF entering and
leaving the interstitia. It was noted that when increasing kL in one
tissue compartment only (e.g., increasing kL,N only from ‘‘Calf Peak
Exercise’’ to ‘‘Peak Exercise’’ in Fig. 9A), the interstitial
concentration of free sVEGFR1 only decreased locally (e.g.,
normal), while slightly increased in the other tissue compartment
(e.g., calf). This was due to a secondary ‘‘spill-over’’ of the elevated
plasma free sVEGFR1 through increased extravasation into the
distal compartment. This may suggest that if increasing kL were to
be explored as a therapeutic means to alleviate calf tissue
accumulation of sVEGFR1, local lymphatic flushing as induced
by leg exercise may be more productive than whole-body exercise
(Fig. 9A).
Distribution changes were again more evident in the blood: the
simultaneous elevations in free VEGF and sVEGFR1, due to
increasing global kL (e.g., 106from control), in turn synergistically
increased sVEGFR1-VEGF complex formation (e.g., 886 from
control), which elevated the complexed fractions of both VEGF
(e.g., +13%) and sVEGFR1 (e.g., +8.7%). In addition, a reversal in
permeability flow of sVEGFR1-VEGF complex, from net intrav-
asation to net extravasation, was also observed upon increasing kL
from control to steady exercise rate (Fig. 9B). In the interstitium, the
fractionalVEGF-occupanciesofVEGFR1 and VEGFR2decreased
,1% within the 100-fold increase in kL tested.
While steady-state analyses showed that plasma concentrations
of sVEGFR1 and VEGF could vary up to 164 pM and 2.4 pM
respectively (.150% about controls) over the physiological range
of kL, we further examined whether concentration ranges of these
magnitudes were attainable within physiological time-course.
6.3. Dynamic effects of lymph flow rates (kL)
A dynamic simulation of the diurnal changes of kL over a
combination of ‘‘bed-rest days’’ and ‘‘active days’’, as illustrated in
Fig. 9C, suggested that physiological variation of kL over the course
of a day can still account for significant variation in plasma
concentrations of VEGF and sVEGFR1. In blood, dynamic
fluctuations in free sVEGFR1 always eclipsed that of free VEGF in
amplitude, at up to 76 vs. 1.65 pM (,76% vs. 110% about
controls). In the interstitia, diurnal ranges of VEGF and sVEGFR1
were much subdued compared to steady-state ranges: free VEGF
varied up to 0.2 pM (,2% about controls), with negligible effects
on VEGF-VEGFR complex formation; while free sVEGFR1
varied up to 2.5 pM (,7% about controls).
It was noted that sVEGFR1 equilibrated slower than VEGF,
such that sVEGFR1 never fully re-established its steady state
within the day, while VEGF reached its new steady state within
hours. This differential characteristic time between VEGF and
sVEGFR1 accounts for the unique responses of the three soluble
species to activity-dependent changes in kL during ‘‘active days’’.
From the waking hour (e.g., 48
th h in Fig. 9C), plasma
concentration of free sVEGFR1 followed a steady rise over the
next 15 h before the onset of sleep. On the other hand, plasma free
VEGF experienced a much steeper initial rise to a transient peak
that closely accompanied the kL peak of early exercise, but soon
falls into a lower plateau as kL also settled to its own steady state of
normal activity. As for the sVEGFR1-VEGF complex in plasma,
its steep initial peak and dip followed those of free VEGF, while a
latter steady rise was driven by the persistent net influx of free
sVEGFR1. In fact, plasma sVEGFR1-VEGF overtook interstitial
sVEGFR1-VEGF at some point near the latter active hours of
wakefulness, whereupon the permeability flow of the complex
reversed in direction to become a net extravasation until the onset
of sleep (Fig. 9C).
In summary, a 15-h period of daytime activity could elevate
plasma concentrations to 42 pM and 1.1 pM above control for
free sVEGFR1 and VEGF respectively. However, 9 h of sleep was
adequate for plasma free sVEGFR1 to fall back to below control
levels regardless of whether the subject was active or inactive
during waking hours (232 pM after bed-rest vs. 216 pM after
activity). Hence, consecutive ‘‘active days’’ negligibly enhanced the
peak sVEGFR1 level attainable in subsequent ‘‘active days’’
(+44 pM sVEGFR1; +1.0 pM VEGF relative to control).
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Increasing direct clearance from blood (kCL) drastically lowered
free VEGF and sVEGFR1 concentrations in plasma (Fig. 10).
These primary effects in blood in turn were propagated into the
interstitium through permeability, i.e., via reduced net sVEGFR1
extravasation and upregulated net VEGF intravasation. Conse-
quently, interstitial concentrations of free sVEGFR1 were
significantly lowered as well; though decreases in interstitial free
Figure 8. Steady-State Effects of Permeability Rate (kP) on VEGF and sVEGFR1 Concentrations (A) & Flows (B). In general, with
increasing kP, concentrations changed in the directions that reduced transendothelial gradients: (i) plasma VEGF concentration increased; (ii) plasma
sVEGFR1 decreased and interstitial sVEGFR1 increased. Exceptions were observed with localized changes in kP – e.g., increasing only kP,Normal from
‘supine(ctrl)’ to ‘fenestration’ enhanced sVEGFR1 extravasation into the normal compartment in expense of that into the calf, causing non-uniform
changes in interstitial sVEGFR1 concentrations (increased locally, decreased distally). ‘Lo’=low; ‘Dep’=dependent; ‘+’=supine (control);
‘Ex’=exercise; ‘Fen’=fenestration; ‘H’=high.
doi:10.1371/journal.pone.0005108.g008
Figure 9. Steady-State and Dynamic Effects of Lymphatic Drainage Rates (kL). Steady-state effects of kL on VEGF and sVEGFR1 concentrations
(A) and flows (B). Of the three transport parameters (kP,k L,k CL), increasing kL over two orders of magnitude about the control value resulted in the
greatest fluctuations in steady-state concentrations: most significantly elevating plasma VEGF and sVEGFR1, while lowering interstitial sVEGFR1.
Exceptions were noted with localized changes in kL – e.g., with increasing only kL,Normal from ‘CP’ to ‘PE’, the enhanced flushing of sVEGFR1 from the
local interstitium into the plasma eventually spilled over through increased sVEGFR1 extravasation into the opposite compartment to elevate
interstitial sVEGFR1 concentration there. In addition, a reversal in permeability flow of sVEGFR1-VEGF complex (red box) was noted for kL above
control. ‘Lo’=low; ‘Nite’=night; ‘+’=supine awake (control); ‘SE’=whole-body steady exercise; ‘CP’=calf-only peak exercise; ‘PE’=whole-body peak
exercise; ‘Hi’=high. Dynamic Effects of kL on VEGF, sVEGFR1, and sR1-VEGF Concentrations (C). kL-driven fluctuations in VEGF and sVEGFR1 attained
within physiological diurnal cycles were less than those attained during steady-state analyses but still were of very wide ranges. ‘‘Bed-rest days’’
(purple columns) consisted of 15 hrs of wakefulness limited to supine or sitting postures, followed by 9 hrs of sleep. ‘‘Active days’’ (yellow columns)
consisted of 15-hrs of activity starting off with a peak in kL during early exercise and settling down to a steady running/walking rate, followed by 9 hrs
of sleep. Reversed permeability flow of sVEGFR1-VEGF complex (red cross-hatching) was observed in the latter active waking hours. ‘‘Calf-limited
activity days’’ (aqua column) are same as ‘‘bed-rest days’’ except that active kL was induced in the calf during the first 15 hrs of wakefulness. Stick-
figure illustrations adapted from Olszewski et al. Lymphology 1977, 10(3):178–183.
doi:10.1371/journal.pone.0005108.g009
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mental flows were masked by the predominant secretion and
internalization flows of VEGF.
Distribution analysis in the blood showed that the number of
sVEGFR1-VEGF complexes reduced proportionally to free
VEGF (sVEGFR1-complexed fraction of total VEGF was
consistent within 2%) while the fractional occupancy of sVEGFR1
dropped from 19% to 2% over the 100-fold variation in kCL. In the
interstitium, the fractional VEGF-occupancies of VEGFRs
decreased ,0.2% for the kCL range tested.
Discussion
Healthy baseline: transendothelial gradients of VEGF and
sVEGFR1
This paper documented our development of an original in silico
multi-tissue model for simulating the systemic distributions of VEGF
and sVEGFR1 for a healthy subject. The unexplained large
variability in literature data of measured plasma concentrations of
VEGF and sVEGFR1 in healthy subjects necessitates a thorough
examination of inter-study differences in experimental protocol. Here
in this study, we have chosen to target the plasma concentrations of
[V]pl=1.5 pM (converted for 46-kDa VEGF homodimers) and
[sR1]pl=100 pM (converted for 200-kDa sVEGFR1 homodimers).
At the control secretion rates of VEGF and sVEGFR1 needed to
reproduce these selected plasma concentrations, our predicted
interstitial concentrations ([V]IS=10pM; [sR1] IS=36 pM) were
inconsistent with levels expected from microdialysis data (,1p M
[135,136]). Technical concerns have been raised regarding the use of
microdialysis membranes of high molecular-weight cut-offs to study
macromolecules such as proteins, including compromised spatial
resolutions associated with large probe sizes and unwanted
ultrafiltration that could alter interstitial space compositions [139].
Until independent experimental validation for interstitial concentra-
tions could be obtained using methods other than microdialysis, we
propose several in silico assumptions-based sources of discrepancy
between our predicted observations vs. microdialysis data for plasma
VEGF below. They fall under these categories: (1) interstitium-to-
blood transporters of VEGF; (2) blood sources of VEGF or
sVEGFR1; (3) interstitial sinks of VEGF and sVEGFR1; and (4)
organ subdivisions of body compartment.
First of all, an unexpected consequence of introducing
sVEGFR1 into the VEGF system was the predicted elevation of
plasma VEGF, counter-intuitive to experimental suggestions that
sVEGFR1 lowers the availability of circulating VEGF in vivo
[8,16,18]. Specifically, tuning [sR1]pl up from 0 to 200 pM was
accompanied by corresponding increases in [V]pl from 1 to 2 pM
(Fig. 3). Analyzing the flow diagrams of the soluble species (Fig. 4),
we postulated that sVEGFR1 – as a diffusible decoy receptor of
VEGF – was able to facilitate transport of VEGF from the tissue
interstitium into blood via either lymph or vascular permeability
flow. It is thus conceivable that other soluble receptors of VEGF
with interstitial origins could similarly facilitate interstitia-to-blood
transport of VEGF – effectively lowering interstitial VEGF and
elevating plasma VEGF – allowing us to target a [V]pl of 1.5 pM
using lower VEGF-secretion rates and consequentially lower [V]IS.
Possible candidates include: (a) human soluble VEGFR2
(160 kDa) – present in significant quantities in healthy human
plasma (7–8 ng/mL) [140] and upregulated in acute myeloid
leukemia [39]; (b) soluble NRP1 (90 kDa) – a VEGF165-specific
antagonist, with documented renal expression in humans
[141,142]; and (c) cellular fibronectin (,500 kDa) – with VEGF-
affinity sites on its heparin-binding domain [124,143] and
normally present in extracellular matrix but can end up in
Figure 10. Steady-state Effects of Plasma Clearance Rate (kCL) on VEGF and sVEGFR1 Concentrations. Increasing kCL resulted in: (i)
drastically lower plasma concentrations of both free VEGF and sVEGFR1, (ii) lower interstitial sVEGFR1 but unchanged interstitial VEGF, and (iii)
reduced transendothelial gradient for VEGF but not for sVEGFR1.
doi:10.1371/journal.pone.0005108.g010
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vascular injury, such as in pre-eclampsia [144].
Furthermore, our model currently has no blood sources of VEGF
or sVEGFR1, which would elevate their respective plasma
concentrations. Thrombin-activated platelets have been known to
release VEGF from their a-granules [145], as well as fibronectin-
VEGF complexes [143], during wound-healing angiogenesis.
Activated peripheral blood mononuclear cells may also be a direct
blood source of sVEGFR1 [17]. Intramuscular production of
sVEGFR1 was assumed in this model to occur entirely through
abluminal endothelial secretion into the interstitium; luminal
endothelial secretion into the circulation is a conceivable direct blood
source of sVEGFR1 but has yet to be quantitatively documented.
Moreover, interstitial proteolytic clearance of soluble or matrix-
bound VEGF – e.g., plasmin- and matrix metalloproteinase
(MMP)-mediated cleavage of VEGF165 and the respective release
of VEGF110 and VEGF113 fragments [95,146], as well as the
intrinsic protein degradation rate of VEGF [147] – was not
considered in the current model. Release of VEGF165 from
interstitial matrix sites through plasmin/MMP degradation of
matrix core proteins was also neglected. Abnormal plasma levels of
MMPs in PAD [148,149] may suggest a role for proteolytic
degradation or release of VEGF165 in causing pathological
bioavailabilities of VEGF. The recent discovery of possible
modulation by MMPs on sVEGFR1’s effects on VEGF-VEGFR2
signaling was also not considered here [150].
Lastly, there may be specialized organs with higher VEGF
production rates which, if separately partitioned from our normal
compartment, may lessen the burden on skeletal muscle for VEGF
production (i.e., VEGF release from tissue to blood, whether via
lymph or vascular permeability). Other adult cell sources where
VEGF expression has been qualitatively described [151] include:
(i) epithelial cells near fenestrated blood vessels (high vascular
permeability), e.g., choroid plexus and kidney glomeruli; and (ii)
cells adjacent to sinusoidal vessels, e.g., in the liver (which
produces half of all lymph formed by the body at rest [93]) and
spleen (also the main site of destruction of platelets [93]). In other
words, the high interstitial VEGF level predicted in our normal
compartment may currently be skewed by lumping skeletal muscle
with these organs of higher interstitial VEGF levels.
Introduction of homodimerized sVEGFR1 and lymphatic
drainage did not drastically alter VEGF ligand and
receptor distributions in healthy muscle tissues
The model extensions to include homodimeric sVEGFR1 and
lymphatic biotransport did not significantly alter our prior steady-
state predictions for healthy muscle tissues [54,59]: that most
extracellular VEGF were surface receptor- or matrix-bound; that
almost all matrix binding sites were unoccupied by VEGF or
sVEGFR1; and that less than a quarter of total receptors on the
abluminal surface (8% of VEGFR1, 20% of VEGFR2, and 18% of
NRP1) were part of VEGF-bound signaling complexes. In its
capacity as a soluble or NRP1-bound trap of VEGF, sVEGFR1 only
h e l ds m a l lf r a c t i o n so ft o t a li n t e r stitial VEGF at control: 0.7% and
3.25% in the normal and calf compartments respectively. However,
the present study did not rule out the possibility that monomeric
sVEGFR1, in its capacity to heterodimerize with surface VEGFR1 or
VEGFR2 monomers, can significantly alter these distributions.
Significant complexed fractions of VEGF and sVEGFR1 in
plasma necessitate re-evaluation of assay specificity
At our simulated healthy control, 77% of total plasma VEGF
was sVEGFR1-complexed and 5% of total sVEGFR1 was VEGF-
bound, both considerably higher than experimentally measured
[45]. The much lower complexed fractions from experimental
data may indicate that in vivo, other soluble receptors (e.g.,
sVEGFR2, sNRP1, plasma fibronectin) can strongly compete with
sVEGFR1 as plasma reservoirs for VEGF, or significant quantities
of other ligands (e.g., PlGF, VEGF-B) are present to compete with
VEGF for sVEGFR1 binding. We propose that the experimental
quantification of all major in vivo binding partners for both VEGF
and sVEGFR1 from peripheral blood samples to be essential in
reconciling the apparent contradiction between predicted and
measured VEGF-sVEGFR1 complexed fractions. Alternatively, if
our computational predictions correctly suggest that the com-
plexed fractions of VEGF and sVEGFR1 were underestimated
experimentally, the implications are that: (1) measurements of free
VEGF and free sVEGFR1 should not be taken as stand-ins for
circulating (free+bound) VEGF and sVEGFR1 levels [45], and
may be insufficient in characterizing disease states; and (2) the
variation in complexed fractions may partially account for the
well-documented heterogeneity in measurements of plasma VEGF
and sVEGFR1. Re-evaluations of assay specificity and protocol
standardization for measuring free vs. complexed sVEGFR1, as
was done for VEGF [152], may be worthwhile.
Simulation of VEGF-trapping did not recapitulate
sVEGFR1’s anti-angiogenic potential
Several experimental studies have demonstrated the ability of
sVEGFR1 as a ligand sink in lowering the availability of free VEGF
in vitro, ex vivo and in vivo [8,16,153], or have implicated this ligand-
trapping mechanism of sVEGFR1 in the pathogenesis of disease
states where inverse changes between VEGF and sVEGFR1
concentrations were generally observed [18]. Thus it was surprising
that in our simulations, upregulated expression of either VEGF or
sVEGFR1 was not accompanied by significant inverse changes in
the systemic levels of the other, as intuitively expected of a straight-
forward ligand-trapping behavior. Instead, increasing VEGF
production rate from the normal tissue compartment led to drastic
increases in sVEGFR1 levels systemically (Fig. 2A). Conversly,
when sVEGFR1 production rates were increased, interstitial VEGF
only decreased minutely while plasma VEGF counter-intuitively
increased drastically (Fig. 3A).
Based on analyses of the flow balances and distribution profiles
at control, we hypothesized that several confounding mechanisms
were obscuring the most direct effects of VEGF-trapping by
sVEGFR1 (i.e., where upregulated expression of one lowers the
availability of the other). In the first scenario where VEGF
production was increased, we postulated that increasing VEGF-
occupancies of NRP1-coupled complexes actually reduced NRP1-
dependent internalization of sVEGFR1, resulting in the non-
intuitive increase in systemic levels of free sVEGFR1. In the
second scenario where sVEGFR1 production was increased, we
postulated that the transendothelial gradients at control were
permissive to the trapping of interstitial VEGF by sVEGFR1 and
the shuttling of the formed complexes into the blood, whereupon
the subsequent dissociation resulted in the non-intuitive increase in
plasma free VEGF. In other words, we hypothesized that the net
tendency for sVEGFR1-VEGF complex association in the tissue
interstitium provided an extra conduit for VEGF to be transported
into the tissue (via its complexed form, in addition to simple
intravasation of free VEGF; see Fig. 4). Thus an immediate future
direction is to perform a thorough mechanistic study to
computationally validate these hypotheses, and to search for the
conditions under which the VEGF-trapping ability of sVEGFR1
can account for reductions in free VEGF within the same
compartment and/or systemically.
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important result was that the intensities of signaling complex
formation (directly proportional to interstitial free VEGF levels)
were negligibly affected by sVEGFR1 production rates (Fig. 3B) –
computational simulation of just the VEGF-trapping interactions
of sVEGFR1 was insufficient to replicate the expected inhibitory
function of sVEGFR1 on VEGF-signaling. Counter to prevailing
wisdom, simulated increase in production of sVEGFR1 did not
lead to significant reduction in intramuscular VEGF-VEGFR2
complex formation. This implication that VEGF-trapping alone
may not account for sVEGFR1’s anti-angiogenic potential needs
to be experimentally validated; while computationally, the next
step would be to investigate whether heterodimerization with
surface VEGFRs is the key to sVEGFR1’s purported contribution
in impaired angiogenesis.
Also worth considering are the functional consequences of the
counter-intuitive increase in plasma VEGF, at the expense of
interstitial VEGF, in response to sVEGFR1 production. While the
current model did not simulate luminal endothelial surface
VEGFRs, their potential in vivo presence (discussed further below)
may suggest the unexpected angiogenic activation of microvascu-
lature in distal tissues by the elevated plasma VEGF as a result of
local intramuscular production of sVEGFR1.
Changing levels of circulating sVEGFR1 may reflect
altered tissue expression of surface receptors
In examining system responses to variations in receptor
expression levels and effective ligand-receptor affinities from control
values, we confirmed that the introduction of sVEGFR1 into the
model did not change previous predictions [54] regarding NRP1
density as a functional ‘‘angiogenic switch’’ of VEGF signaling in
skeletal muscle tissue (Fig. 3B). We alsodemonstrated that the newly
proposed VEGF121-NRP1 affinity has a negligible effect on the
VEGFsignalingprofiles(Fig.4D,E).WefurthershowedthatNRP1-
dependent internalization of sVEGFR1 can be a major regulator of
free sVEGFR1 levels in both interstitia and plasma, both directly
(e.g., varying NRP1 densities) and indirectly (e.g., R2/R1 ratio and
VEGF-VEGFR1bindingaltertheavailabilityofuncoupledNRP1s)
(Fig. 5A, 6B). The clinical implication is that pathological levels of
plasma sVEGFR1 may not necessarily indicate altered sVEGFR1
production or altered availability of free VEGF, because they may
partially reflect altered receptor expression in tissues. This will likely
be even more significant when sVEGFR1-heterodimerization with
surface receptors are considered.
Implications of model assumptions for surface receptors
Here we discuss several assumptions made in the current
modeling of surface receptors – (1) static receptor internalization
and insertion (conservation of total receptor density), (2) no
intracellular trafficking & signaling, (3) no receptor heterodimers,
(4) no luminal surface receptors – and in particular, their relevance
to the study of sVEGFR1.
Firstly, our current implementation assumed constant inter-
nalization rates for all receptors and complexes, paired with
constant free receptor insertion rates (free VEGFR1, free
VEGFR2, free NRP1) defined to conserve the total receptor
densities (total VEGFR1, total VEGFR2, total NRP1) at the cell
surface. This conservation assumption – i.e., the artificial
maintenance of a fixed total receptor density irrespective of the
interstitial free VEGF concentration or the degree of receptor
activation – had implicitly driven the magnitudes of the
internalization flows of soluble species in the tissue compart-
ments. Future investigation is needed to quantify whether the
large values of VEGF internalization flows predicted in this study
critically depended on the modeled internalization rates and
conservation assumptions. Adjustments to the internalization
flows of VEGF could significantly alter the secretion flows of
VEGF needed to maintain the same steady-state interstitial
VEGF concentrations, and in turn significantly shift the tissue
f l o wb a l a n c eo nF i g .4 ,s u c ht h a ti nterstitial VEGF might acquire
acute sensitivity to transport parameters, as well as to depletory
ligand-trapping by sVEGFR1, against our current findings.
There is also justification for beginning investigations into
dynamic regulation of receptor internalization, in particular for
VEGFR2: VEGF-induction of VEGFR2 internalization has
been shown in various studies as receptor tyrosine kinase
(RTK) autophosphorylation-, dynamin-, clathrin- and
VEGFR1-mediated processes [154–157]. Particularly relevant
is the latter process of regulation through VEGFR1-VEGFR2
crosstalk, which possibly presents an opportunity for sVEGFR1,
as a VEGFR1 competitor, to moderate VEGFR2 activation and
internalization.
Secondly, our network of biochemical interactions ended at the
level of ligand-receptor binding and complex internalization. Thus
far we have used the cell surface densities of VEGF-VEGFR
complexes as surrogate markers for ‘‘angiogenic signaling
potential’’ [158]; however, there is increasing experimental
information on intracellular VEGF signaling, whose contribution
can only be assessed with detailed model extensions to keep track
of endosomal and caveolar populations of internalized complexes,
as well as VEGF-regulated sorting towards degradation, nuclear
translocation, or recycling back to the cell surface [159,160].
Thirdly, there is recent in vitro and in silico evidence supporting
significant prevalence of VEGFR1-VEGFR2 heterodimers on
endothelial cell surfaces, with signaling properties distinct from
those of VEGFR homodimers [68,70,94]. Receptor heterodimers
were neglected in this model for the lack of in vivo quantification of
their relative abundance, and would not have affected current
predictions of sVEGFR1’s effects on the VEGF system until the
focus of study switches to sVEGFR1’s alternate role in hetero-
dimerizing with surface VEGFRs.
Lastly, in this study, all receptors were confined to the abluminal
endothelial cell surface, in congruence to experimental studies
inferring abluminal localization of VEGFRs based on VEGF
immunostaining [161] and the common assumption that VEGFRs
signaling respond more to local/interstitial VEGF concentrations
rather than circulating/plasma VEGF [152]. However, this
assumption needs to be thoroughly re-evaluated, in light of recent
VEGFR2-immunostaining that localized VEGFR2 equally on
luminal and abluminal surfaces of tumor- and adenoVEGF-
induced microvascular endothelium, as well as significantly on
transendothelial vesiculovaculolar organelles (VVOs) and lumin-
ally-attached caveolae [162]. It is unclear whether VEGFR1 and
NRP1 also have significant luminal populations, or whether
luminal redistribution follows the caveolin-1-dependent internal-
ization unique to VEGFR2 [158]. If luminal expression of
VEGFR1 is considered in the future, luminal secretion of
sVEGFR1 should be simultaneously investigated as well. Interest-
ingly, a possible luminal bias in Nedd4-stimulated VEGFR2
degradation has also been postulated [158]. Although it is
uncertain whether luminal vs. abluminal VEGFR2 have equal
signaling potential or similar downstream targets [162], there is
urgent need to explore the possibility, especially in the next step of
investigating sVEGFR1-heterodimerization with surface recep-
tors, i.e., given the much higher predicted sVEGFR1 concentra-
tion in plasma than in the interstitium, the luminal extent of
sVEGFR1-VEGFR heterodimerization would be expected to
exceed that on the abluminal side.
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gradients by 10% at most
We showed that the densities and affinities of the interstitial matrix
binding sites did not affect steady-state predictions of plasma and
interstitial levels of the soluble species, nor VEGFR occupancies. We
also showed consistently minuscule fractional occupancies of total
matrix proteoglycan sites, i.e., VEGF and sVEGFR1 proteins are
always hugely outnumbered by glycosaminoglycan binding-sites in
the interstitial matrix. To the extent that the present study focuses on
sVEGFR1’s effect on the formation of surface VEGF signaling
complexes,the uncertainties in the characterization of matrix sites are
not of concern. However, the absolute quantities of matrix-bound
VEGF165 and sVEGFR1 – comprising 36% and 72% of total
VEGF165 in the normal and calftissuesrespectively,as wellas 97%of
total sVEGFR1 in either tissue – were greatly sensitive to matrix site
densities and affinities (Fig. 7).The sizes of matrix-bound reservoirs of
VEGF and sVEGFR1 may affect the time course of dynamic
concentration changes in free VEGF, free sVEGFR1 or surface
signaling complexes. Although the compartmental model did not
include the spatial resolution needed to examine interstitial VEGF
gradients,the in vivo distribution of matrix sites between the ECMand
BMs could affect spatial morphogenic gradients that guide sprouting
angiogenesis. In fact, a recent study attributed the ability of
sVEGFR1 in rescuing the branching morphogenesis of developing
vessels in VEGFR1
2/2 mutant embryonic cell cultures to
sVEGFR1’s role as a diffusible VEGF sink: that by diffusing away
from the cell surface, it is able to alter the interstitial VEGF gradients
as presented to endothelial tip cell filopodia of sprouting vessels [163].
The present model was not able to directly address the
modulating effects of sVEGFR1 on the matrix-bound VEGF
gradients, because we did not model the subsequent binding of
sVEGFR1 to matrix-bound VEGF (forming M?V?sR1), due to
insufficient experimental knowledge about its hypothetical binding
configuration – e.g., whether the sVEGFR1-binding domain of
VEGF is still exposed after matrix-association, and whether
subsequent sVEGFR1 binding can effectively mask or protect the
matrix-bound VEGF from participating in capillary sprout
guidance. However, considering that the ratio of interstitial free
sVEGFR1 to matrix-bound VEGF was ,1:12.5 (Fig. S2), even the
hypothetical recruitment of all available sVEGFR1 would only
attenuate the matrix gradient of VEGF by ,10% (non-
equilibrated). Ignoring all other compensating interactions and
processes in the molecular system, and assuming Kd(M?V,sR1)
,Kd(V,sR1), a simple equilibrium approximation of sVEGFR1
attenuation of matrix-bound VEGF would be ,7.5%:
Kd M:V,sR1 ðÞ ~
M:V ½ 
’: sR1 ½ 
’
M:V:sR1 ½ 
’ ~
M:V ½  {x ðÞ : sR1 ½  {x ðÞ
x
33 pM~
*500 pM{x ðÞ : *40 pM{x ðÞ
x
[x*37:5p M
M:V:sR1 ½ 
’
M:V ½ 
*
37:5p M
500 pM
~7:5%
Physiological variations in transport rates affected the
stability and reliability of plasma VEGF and sVEGFR1 as
diagnostic markers
We showed that both free VEGF and free sVEGFR1 levels in
plasma varied significantly over the tested physiological ranges of
transport parameters: e.g., the activity-dependent kL changes
typically experienced during an active day led to fluctuations in
[sR1]pl and [V]pl of up to 76 pM and 1.65 pM about their healthy
control levels of 100 pM and 1.5 pM respectively (Fig. 9B). This
indicated that normal inter-patient variations in permeability and
lymph flow rates – as dependent on patients’ physical activity
levels (sedentary vs. active lifestyle), posture during blood
sampling, etc. – may contribute to the physiological heterogeneity
in the clinical measurements of plasma VEGF and sVEGFR1
among healthy control cohorts. Corrections for these factors may
yield more stable and consistent healthy benchmarks for the use of
plasma VEGF or sVEGFR1 as diagnostic markers.
On the other hand, interstitial VEGF levels remained
unchanged over the physiological variations in transport rates,
because the predicted secretion and internalization flows of VEGF
dominated over all its inter-compartmental transport flows. These
relative flow magnitudes have not been experimentally validated;
in vivo quantification of VEGF secretion rates would be invaluable
to assess our targeted secretion rates which were highly dependent
on the chosen initial configurations of internalizable receptors.
When interstitial VEGF is unresponsive to changes in transport
rates, so is the predicted formation of signaling complexes on the
tissue endothelia. The significance here is that the physiological
variation in transport rates offers a case example where the
common circulating angiogenic markers become unreliable, i.e.,
apparent changes in free VEGF or sVEGFR1 levels in the plasma
do not correlate with changes in the actual angiogenic signaling
potential in the tissues. However, considering the significant
sensitivity of interstitial sVEGFR1 to transport rates, we cannot
rule out the possibility that once sVEGFR1-heterodimerization
with surface VEGFRs is in place, that transport rates may indeed
affect the formation of signaling complexes in muscles.
As a first assessment of whether activity-dependent kL can
account for the surge in plasma sVEGFR1 observed after acute
exercise in healthy individuals, simulations were performed
without concurrent exercise-induced changes to sVEGFR1 or
VEGF production, kP, or receptor expression. Immediately after
the onset of exercise, independent simulation of activity-dependent
kL predicted that an elevation in [V]pl preceded the larger but
slower elevation in [sR1]pl (Fig. 9B). In contrast, a human study
[49] showed acute exercise to cause a fast ,50% elevation in
[sR1]pl (peaking ,0.5 h after exercise) which preceded a
temporary ,50% drop in [V]pl (lowest at ,2 h after exercise).
Thus our simulated kL-induced increase in [sR1]pl roughly
matched that in the exercise study in magnitude but not in speed;
while our kL-induced changes in [V]pl was in opposite direction to
those in the exercise study. This may suggest that hypoxia-induced
secretion of sVEGFR1 (as opposed to lymphatic drainage of
sVEFR1) is indeed the faster and major source of elevated plasma
sVEGFR1 in exercise; but our simulations were unable to confirm
the conclusion by Bailey et al. [49] that VEGF trapping by the
surge of sVEGFR1 had caused the drop in plasma VEGF. In any
case, the fact that lower kL’s associated with inactivity led to lower
plasma sVEGFR1 (Fig. 9B) supported the possibilities that: (i)
PAD-associated immobility may contribute to the lower plasma
sVEGFR1 seen in PAD patients, although it remains to be
experimentally validated whether a corresponding accumulation
of interstitial sVEGFR1 and consequential impairment of muscle
angiogenesis would occur; and that (ii) exercise rehabilitation may
partly reverse the pathological levels of circulating angiogenic
markers through activity-induced kL, thereby ameliorating the
angiogenic state in PAD patients. If future considerations of
sVEGFR1 heterodimerization with surface VEGFR can establish
a link between transport-dependent fluctuations in sVEGFR1
Systemic Effects of sVEGFR1
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would be significant: e.g., therapeutic delivery of VEGF-C/D (the
VEGF family members involved in lymphangiogenesis) alongside
VEGF-A to ischemic tissues could be explored for synergistic
effects of increased lymph flow on the angiogenic efficacy of
VEGF-A.
Limitations in model assumptions that can affect the above
conclusions include: underestimations of the effective control kL
and kP due to lumping of highly-perfused organs with skeletal
muscle tissue in the normal compartment; overestimation of
whole-body exercise-induced increases in kL and kP as non-skeletal
muscle organs (e.g., liver) should maintain resting rates; and
misestimation of clearance rates of sVEGFR1 and sVEGFR1-
VEGF from the plasma half-lives of synthetic soluble VEGF-traps.
Future directions
The immediate task is to perform a computational mechanistic
study to investigate why simulations of VEGF-trapping by
sVEGFR1 did not demonstrate any purported anti-angiogenic
effects: Does interstitium-to-blood shuttling of VEGF-sVEGFR1
complexes explain the apparent absence of local reductions in free
VEGF upon increased interstitial sVEGFR1 production? Are
there alternate conditions under which sVEGFR1, as a VEGF
sink, can indeed dampen VEGF signaling as in vitro and ex vivo
experiments have suggested?
sVEGFR1-heterodimerization of surface VEGFRs is expected
to present an alternative way for sVEGFR1 to modulate VEGF
signal transduction even when interstitial free VEGF levels remain
high, by effectively reducing the availability of functional
endothelial surface VEGFR dimers for VEGF activation,
assuming that VEGFR heterodimers with sVEGFR1 cannot
signal. These effects are likely to be heavily determined by the
proportionality of sVEGFR-VEGFR1 vs. sVEGFR-VEGFR2
binding; that is, any bias in the coupling of sVEGFR1 to
VEGFR1 or VEGFR2 would tilt VEGF-activated signaling in the
direction of the other receptor. Thus the next step would be to
extend the model to quantify the contribution of this hetero-
dimerization mechanism to sVEGFR1’s anti-angiogenic potential.
Table 12 compares our significant computational predictions
with current experimental data; future experiments to address the
proposed sources of discrepancies are recommended. With future
availability of experimental validation to address the current
limitations in model assumptions, the multi-compartmental model
put forth in this study can be more finely tuned to accurately
represent human subjects – healthy or diseased – to serve as a
computational platform for design and testing of integrative pro-
angiogenic therapies.
Supporting Information
Figure S1 Healthy Subject: Complete Molecular Distribution
Analysis for Varying VEGF Secretion Rates. (A) Free VEGF and
free sVEGFR1 distributions. (B) Total sVEGFR1 distribution. (C)
Total VEGF121 distribution. (D) Total VEGF165 distribution. (E)
Extracellular matrix binding site occupancies. (F) Endothelial
basement membrane binding site occupancies. (G) Parenchymal
basement membrane binding site occupancies. (H) VEGFR1
occupancies. (I) VEGFR2 occupancies. (J) NRP1 occupancies. (K)
VEGF-bound VEGFR complexes.
Found at: doi:10.1371/journal.pone.0005108.s001 (0.15 MB
PDF)
Figure S2 Healthy Subject: Complete Molecular Distribution
Analysis for Varying sVEGFR1 Secretion Rates. (A) Free VEGF
and free sVEGFR1 distributions. (B) Total sVEGFR1 distribution.
(C) Total VEGF121 distribution. (D) Total VEGF165 distribution.
(E) Extracellular matrix binding site occupancies. (F) Endothelial
basement membrane binding site occupancies. (G) Parenchymal
basement membrane binding site occupancies. (H) VEGFR1
occupancies. (I) VEGFR2 occupancies. (J) NRP1 occupancies. (K)
VEGF-bound VEGFR complexes.
Found at: doi:10.1371/journal.pone.0005108.s002 (0.15 MB
PDF)
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Table 12. Comparing Computational Predictions with Experimental Data.
Computational Predictions Experimental Data Possible Explanations of Discrepancy
Interstitial VEGF in muscle, [V]IS=10pM [V] IS,1 pM based on microdialysis [135,136] Technical issues with macromolecular measurements using
microdialysis; Model overestimation of sVEGFR1-facilitated
transport of VEGF; Missing blood sources of VEGF in model.
77% of total plasma VEGF was sVEGFR1-
complexed
,4% mole fraction [45] Other unmodeled soluble receptors (e.g., sVEGFR2, sNRP1,
plasma fibronectin) compete for VEGF in vivo.
5% of total plasma sVEGFR1 was
VEGF-bound
,0.65% mole fraction [45] Other unmodeled ligands (e.g., PlGF, VEGF-B) compete for sVEGFR1
in vivo.
sVEGFR1 as a ligand sink negligibly
reduced interstitial free VEGF while
drastically elevating plasma free VEGF
sVEGFR1 as a ligand sink lowers availability
of free VEGF in vitro, ex vivo and in vivo
[8,16,153]
Computational model examined transport between tissue and blood
compartments; Experimental setups examined single-compartment
(e.g. pooled amniotic fluids) or relatively closed system (e.g.,
avascular cornea) systems.
sVEGFR1 did not reduce intramuscular
VEGF-VEGFR2 complex formation
sVEGFR1 is anti-angiogenic (cornea [16], pre-
eclampsia [17,18], cancer [21–30])
Current computational model neglected sVEGFR1-
heterodimerization with surface VEGFRs.
Exercise-induced lymph flow rates elevated
plasma VEGF faster than plasma sVEGFR1
Acute exercise quickly elevated plasma
sVEGFR1, then reduced plasma VEGF [49]
Other exercise-induced parameter changes (e.g., hypoxia-induced
sVEGFR1 production) not modeled computationally.
doi:10.1371/journal.pone.0005108.t012
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